



(51) International Patent Classification:

A61K 48/00 (2006.01)

A61K 9/127 (2006.01)

A61K 9/00 (2006.01)

A61K 31/7052 (2006.01)

A61K 9/51 (2006.01)

A61K 31/7105 (2006.01)

C12N 15/00 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2023/053639

(22) International Filing Date:

14 February 2023 (14.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22156604.5

14 February 2022 (14.02.2022) EP

(71) Applicant: PANTHERNA THERAPEUTICS GMBH

[DE/DE]; Neuendorfstrasse 20b, 16761 Hennigsdorf (DE).

(72) Inventors: FEHRING, Volker; Bouchestraße 77, 12435

Berlin (DE). KEIL, Oliver; Bertramstraße 112 A, 13467

Berlin (DE). KAUFMANN, Jörg; Gutshofstraße 13, 13465

Berlin (DE). MOGA, Akanksha; Stiftestraße 2, 14471

Potsdam (DE).

(74) Agent: BOHMANN, Armin K.; Nymphenburger Str. 1,

80335 München (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: PREPARATION FOR USE IN A METHOD FOR THE TREATMENT AND/OR PREVENTION OF A DISEASE

(57) Abstract: The present invention is related to a preparation for use in therapy, wherein therapy comprises local administration of the preparation to a subject, wherein the local administration is selected from the group consisting of intramuscular administration, subcutaneous administration, intravitreal administration, intrathecal administration, intratumoral administration, intracerebral administration and intradermal administration, wherein the preparation comprises lipid nanoparticles, wherein the lipid nanoparticles comprise a lipid composition comprising a first and a second lipid, and a therapeutically active nucleic acid molecule, and, wherein the lipid nanoparticles are amphoteric, overall neutrally charged lipid nanoparticles.



Preparation for use in a method for the treatment and/or prevention of a disease

[001] The present invention is related to a preparation comprising a payload molecule and a lipid composition, the preparation for local delivery of the payload, the preparation for use in a method for the treatment and/or prevention of a disease, the preparation for use in a method for local delivery of the payload, a pharmaceutical composition comprising the preparation, the pharmaceutical composition for local delivery of the payload, the pharmaceutical composition for use in a method for the treatment and/or prevention of a disease, and a method for preparing said preparation.

[002] Currently applied lipid nanoparticles (LNPs) for the intramuscular, subcutaneous, and intradermal administration of RNA are based on strongly cationic and even more often on pH-sensitive cationic lipids, also called ionizable cationic lipids.

[003] The strongly cationic LNPs are made of a lipid system that contains beside neutral co-lipids and PEGylated lipids a strong cationic lipid. The pKa of said strong cationic lipid is usually above 9 which means that said cationic lipid is positively charged over a broad pH range. Such strong cationic lipid is thus positively charged at acidic (pH 3 to 6.7) and neutral pH values (pH 6.8 to 7.4) and do even show permanent cationic properties at mild (pH 7.5 to 8) and medium basic (pH 8.1 to 10) pH values. This characteristic allows a strong complexation of overall negatively charged ribonucleic acids (RNAs) and a strong interaction with overall negatively charged cell membrane, like endosomal membranes, that are intended to be transfected by LNPs comprising such strong cationic lipids. However, the strong cationic charges of this type of lipid interact with other negatively charged components such as extracellular substances like proteins, whereupon the complex comprising RNA and lipids rapidly dissociates, and the thus released RNA is rapidly degraded. Such interaction with negatively charged extracellular substances may also lead to aggregation of the lipid nanoparticles, hence inhibiting a functional uptake of the LNPs into the target cells.

[004] On the other hand, pH-sensitive cationic LNPs are made of neutral co-lipids, PEGylated lipids and an ionizable cationic lipid that is characterized by a typical pKa value between 8 and 9.5. Due to the relatively low pKa value, such cationic lipid is positively charged at acidic pH values (typically at a pH of 4.5 to 5.5) and at these acidic pH values it is capable of interacting electrostatically with RNAs, or complexing RNAs and forming LNPs that encapsulate RNA, accordingly. Once the LNPs are formed and the pH of the suspension medium is adjusted to a neutral pH value, the pH-sensitive lipids at the surface of the LNPs are losing their positive charges, e.g., due to deprotonation of amino groups, whereas the RNAs are still entrapped inside the LNP particle. As a result, the LNP surface can be described as rather neutral and hydrophobic. These LNPs are originally designed as hepatocyte targeting LNPs for intravenous application and are known for their strong interaction with hydrophobic substances like ApoE.

[005] The problem underlying the present invention is the provision of a means for delivering a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[006] Another problem underlying the present invention is the provision of a means suitable for local administration of a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[007] Another problem underlying the present invention is the provision of a means for local administration of a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[008] Another problem underlying the present invention is the provision of a means suitable for local delivery of a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[009] Another problem underlying the present invention is the provision of a means for local delivery of a payload, preferably a payload which is negatively charged at a neutral or

physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[0010] Another problem underlying the present invention is the provision of a means suitable for the treatment and/or prevention of a disease, wherein treatment and/or prevention of a disease comprises local administration of a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[0011] Another problem underlying the present invention is the provision of a means for the treatment and/or prevention of a disease, wherein treatment and/or prevention of a disease comprises local administration of a payload, preferably a payload which is negatively charged at a neutral or physiological pH value, more preferably the payload is a nucleic acid molecule and most preferably an RNA molecule.

[0012] A still further problem underlying the present invention is the provision of a method for producing such means.

[0013] These and other problems are solved by the subject matter of the attached independent claims; preferred embodiments may be taken from the attached dependent claims.

[0014] Furthermore, these and other problems are also solved by the subject matter of the following aspects and embodiments thereof.

[0015] The problem underlying the present invention is solved in a first aspect, which is also a first embodiment of the first aspect, by a preparation comprising a payload molecule and a lipid composition, wherein the lipid composition comprises a first lipid and a second lipid, wherein the first lipid is an anionic lipid having at least one molecular moiety with a pKa value between 4 and 7, and the second lipid is (a) a cationic lipid having at least one molecular moiety with a pKa value between greater 9.5 and 13.5, or (b) a cationic lipid which is pH-independently positively charged.

[0016] In a second embodiment of the first aspect which is also an embodiment of the first embodiment of the first aspect, the pKa value of the first lipid is between 5 and 7.

[0017] In a third embodiment of the first aspect which is also an embodiment of the first and the second embodiment of the first aspect, the pKa value of the first lipid is between 5.5 and 6.5.

[0018] In a fourth embodiment of the first aspect which is also an embodiment of the first, second and third embodiment of the first aspect, the pKa value of the at least one molecular moiety of the second lipid is $9.5 < \text{pKa} \leq 13.5$, preferably the pKa value is between 9.8 and 13.2.

[0019] In a fifth embodiment of the first aspect which is also an embodiment of the first, second, third and fourth embodiment of the first aspect, the pKa value of the at least one molecular moiety of the second lipid is between 10 and 13.

[0020] In a sixth embodiment of the first aspect which is also an embodiment of the first, second and third embodiment of the first aspect, the second lipid is a lipid which is pH-independently positively charged.

[0021] In a seventh embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth and sixth embodiment of the first aspect, the first lipid is bearing at least one negative charge.

[0022] In an eighth embodiment of the first aspect which is also an embodiment of the seventh embodiment of the first aspect, the first lipid is bearing at least one negative charge at a neutral pH value.

[0023] In a ninth embodiment of the first aspect which is also an embodiment of the eighth embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably a pH value of about 6.9 to about 7.5, more preferably a pH value of about 7.2 to about 7.5.

[0024] In a tenth embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth and ninth embodiment of the first aspect, the second lipid is bearing at least one positive charge.

[0025] In an eleventh embodiment of the first aspect which is also an embodiment of the tenth embodiment of the first aspect, the second lipid is bearing at least one positive charge at a neutral pH value.

[0026] In a twelfth embodiment of the first aspect which is also an embodiment of the eleventh embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably a pH value of about 6.9 to about 7.5, more preferably a pH value of about 7.2 to about 7.5.

[0027] In a 13th embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh and twelfth embodiment of the first aspect, the first lipid is bearing at least one carboxylic group.

[0028] In a 14th embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth and 13th embodiment of the first aspect, preferably of the 13th embodiment of the first aspect, the second lipid is bearing at least one group selected from the group comprising an amino group, an imino group, a guanidino group, an amino group substituted with an alkyl group, an imino group substituted with an alkyl group and a guanidino group substituted with an alkyl group.

[0029] In a 15th embodiment of the first aspect which is also an embodiment of the 14th embodiment of the first aspect, the alkyl group is a straight and/or branched chain C1, C2, C3 or C4 hydrocarbon group.

[0030] In a 16th embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th and 15th embodiment of the first aspect, the lipid composition comprises a third lipid.

[0031] In a 17th embodiment of the first aspect which is also an embodiment of the 16th embodiment of the first aspect, the third lipid is a neutral lipid.

[0032] In an 18th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th and 17th embodiment of the first aspect, the lipid composition comprises a fourth lipid.

[0033] In a 19th embodiment of the first aspect which is also an embodiment of the 18th embodiment of the first aspect, the fourth lipid is a PEGylated lipid.

[0034] In a 20th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th,

16th, 17th, 18th and 19th embodiment of the first aspect, the lipid composition forms lipid nanoparticles.

[0035] In a 21st embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th and 19th embodiment of the first aspect, the lipid composition comprises lipid nanoparticles.

[0036] In a 22nd embodiment of the first aspect which is also an embodiment of the 20th embodiment and the 21st embodiment of the first aspect, a surface of the lipid nanoparticles provides about a same number of positive charges and of negative charges.

[0037] In a 23rd embodiment of the first aspect which is also an embodiment of the 22nd embodiment of the first aspect, the surface of the lipid nanoparticles is an outer surface of the lipid nanoparticles.

[0038] In a 24th embodiment of the first aspect which is also an embodiment of the 20th and the 21st embodiment of the first aspect, about a same number of positive charges and of negative charges is present on a surface of the lipid nanoparticles.

[0039] In a 25th embodiment of the first aspect which is also an embodiment of the 24th embodiment of the first aspect, the surface of the lipid nanoparticles is an outer surface of the lipid nanoparticles.

[0040] In a 26th embodiment of the first aspect which is also an embodiment of the 22nd, 23rd, 24th and 25th embodiment of the first aspect, the number of positive charges and of negative charges is the number of positive (cationic) and negative (anionic) charges each at a neutral pH value.

[0041] In a 27th embodiment of the first aspect which is also an embodiment of the 26th embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably of about 6.9 to about 7.5, more preferably of about 7.2 to about 7.5.

[0042] In a 28th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th and 27th embodiment of the first aspect, the lipid composition comprises the first and the second lipid in a dispersion medium.

[0043] In a 29th embodiment of the first aspect which is also an embodiment of the 28th embodiment of the first aspect, the dispersion medium comprises the lipid nanoparticles.

[0044] In a 30th embodiment of the first aspect which is also an embodiment of the 28th and the 29th embodiment of the first aspect, the dispersion medium comprises a continuous phase.

[0045] In a 31st embodiment of the first aspect which is also an embodiment of the 30th embodiment of the first aspect, the continuous phase comprises a pharmaceutically acceptable aqueous buffer system, preferably the buffer system has a physiological pH value and isoosmolar strength and further comprises a cryoprotectant, more preferably the buffer system has a pH value of 7.0 to 7.4 and an osmolality of 250 to 330 mosmol/kg and comprises a cryoprotectant selected from a group comprising sucrose and trehalose, and even more preferably the buffer system is a 10 mM phosphate or 10 mM TRIS/HCl buffer of pH 7.4 and comprises 270 mM Sucrose as cryoprotectant.

[0046] In a 32nd embodiment of the first aspect which is also an embodiment of the 28th, 29th, 30th and 31st embodiment of the first aspect, the pH value of the dispersion medium is a neutral pH value.

[0047] In a 33rd embodiment of the first aspect which is also an embodiment of the 32nd embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably of about 6.9 to about 7.5, more preferably of about 7.2 to about 7.5.

[0048] In a 34th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd embodiment of the first aspect, the molar ratio of the first lipid to the second lipid is such that the number of negative (anionic) charges provided by the lipid composition and the number of positive (cationic) charges provided by the lipid composition is about identical.

[0049] In a 35th embodiment of the first aspect which is also an embodiment of the 34th embodiment of the first aspect, the molar ratio of the first lipid of the lipid composition to the second lipid of the lipid composition is such that the number of negative charges provided by the lipid composition on a surface of the lipid nanoparticles is about the same as the number of positive charges provided by the lipid composition on a surface of the lipid nanoparticles.

[0050] In a 36th embodiment of the first aspect which is also an embodiment of the 35th embodiment of the first aspect, the surface of the lipid nanoparticles is an outer surface of the lipid nanoparticles.

[0051] In a 37th embodiment of the first aspect which is also an embodiment of the 35th and the 36th embodiment of the first aspect, the number of negative charges provided by the lipid composition on a surface of the lipid nanoparticles is about the same as the number of positive charges provided by the lipid composition on a surface of the lipid nanoparticles at a neutral pH value.

[0052] In a 38th embodiment of the first aspect which is also an embodiment of the 37th embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably of about 6.9 to about 7.5, more preferably of about 7.2 to about 7.5.

[0053] In a 39th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd embodiment of the first aspect, the molar ratio of the first lipid to the second lipid is such that the number of negative (anionic) charges of the lipid composition and the number of positive (cationic) charges of the lipid composition is about identical.

[0054] In a 40th embodiment of the first aspect which is also an embodiment of the 39th embodiment of the first aspect, the molar ratio of the first lipid of the lipid composition to the second lipid of the lipid composition is such that the number of negative charges of the lipid composition on a surface of the lipid nanoparticles is about the same as the number of positive charges of the lipid composition on a surface of the lipid nanoparticles.

[0055] In a 41st embodiment of the first aspect which is also an embodiment of the 40th embodiment of the first aspect, the surface of the lipid nanoparticles is an outer surface of the lipid nanoparticles.

[0056] In a 42nd embodiment of the first aspect which is also an embodiment of the 40th and the 41st embodiment of the first aspect, the number of negative charges of the lipid composition on a surface of the lipid nanoparticles is about the same as the number of positive charges of the lipid composition on a surface of the lipid nanoparticles at a neutral pH value.

[0057] In a 43rd embodiment of the first aspect which is also an embodiment of the 42nd embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably of about 6.9 to about 7.5, more preferably of about 7.2 to about 7.5.

[0058] In a 44th embodiment of the first aspect which is also an embodiment of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd and 43rd embodiment of the first aspect, the lipid nanoparticles are amphoteric lipid nanoparticles.

[0059] In a 45th embodiment of the first aspect which is also an embodiment of the 44th embodiment of the first aspect, the lipid nanoparticles are amphoteric lipid nanoparticles at a pH value of about 7 to about 8, preferably at a pH of about 7.4

[0060] In a 46th embodiment of the first aspect which is also an embodiment of the 44th and the 45th embodiment of the first aspect, the amphoteric lipid nanoparticles are overall neutrally charged lipid nanoparticles.

[0061] In a 47th embodiment of the first aspect which is also an embodiment of the 46th embodiment of the first aspect, the amphoteric lipid nanoparticles are overall neutrally charged lipid nanoparticles at a pH value of about 7 to about 8, preferably at a pH of about 7.4.

[0062] In a 48th embodiment of the first aspect which is also an embodiment of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th and 47th embodiment of the first aspect, the first lipid is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid is bearing three functional groups which are protonated in a pH-dependent manner, wherein the lipid nanoparticles have a pH-dependent overall surface charge as subject to diagram (I) shown in Fig. 3.

[0063] In a 49th embodiment of the first aspect which is also an embodiment of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th and 47th embodiment of the first aspect, the first lipid is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid is bearing two functional groups which are protonated in a pH-dependent manner, wherein the lipid nanoparticles have a pH-dependent overall surface charge as subject to diagram (II) shown in Fig. 4.

[0064] In a 50th embodiment of the first aspect which is also an embodiment of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th and 47th embodiment of the first aspect, the first lipid is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid is bearing one functional group which is protonated in a pH-dependent manner, wherein the lipid nanoparticles have a pH-dependent overall surface charge as subject to diagram (III) shown in Fig. 5.

[0065] In a 51st embodiment of the first aspect which is also an embodiment of the 48th, 49th and 50th embodiment of the first aspect, the pH-dependent overall surface charge of the lipid nanoparticles results from the negative charges provided by the first lipid of the lipid composition and from the positive charges provided by the second lipid of the lipid composition.

[0066] In a 52nd embodiment of the first aspect which is also an embodiment of the 48th, 49th, 50th and 51st embodiment of the first aspect, the overall surface charge of the lipid nanoparticles is the overall surface charge of the lipid particles present in the dispersion medium.

[0067] In a 53rd embodiment of the first aspect which is also an embodiment of the 52nd embodiment of the first aspect, the overall surface charge of the lipid nanoparticles is the overall charge of an outer surface of the lipid nanoparticles.

[0068] In a 54th embodiment of the first aspect which is also an embodiment of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd and 53rd embodiment of the first aspect, the lipid nanoparticles are hydrophilic nanoparticles.

[0069] In a 55th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd and 54th embodiment of the first aspect, the preparation comprises lipid nanoparticles, wherein the lipid nanoparticles comprise a lipid composition and optionally a therapeutically active agent, and, at a pH of between 7 and 8, the nanoparticles are amphoteric overall neutrally charged lipid nanoparticles,

wherein the lipid composition comprises a first lipid and a second lipid,

wherein the first lipid is selected from the group consisting of a monoester of a cholesterol with a dicarboxylic acid, an alkyl carboxylic acid, an alkenyl carboxylic acid, a monoester of a diacyl glycerol ester with a dicarboxylic acid, and a diacyl phosphatidylalcohol;

wherein the second lipid is a lipid bearing more than one cationic charge; and

wherein preferably the therapeutically active agent is a therapeutically active nucleic acid molecule.

[0070] In a 56th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th and 55th embodiment of the first aspect, the first lipid is a monoester of a cholesterol with a dicarboxylic acid.

[0071] In a 57th embodiment of the first aspect which is also an embodiment of the 56th embodiment of the first aspect, the dicarboxylic acid of the monoester of a cholesterol with a dicarboxylic acid is selected from the group consisting of succinic acid, glutaric acid and adipic acid.

[0072] In a 58th embodiment of the first aspect which is also an embodiment of the 57th embodiment of the first aspect, the monoester of a cholesterol with a dicarboxylic acid is cholesterol hemisuccinate.

[0073] In a 59th embodiment of the first aspect which is also an embodiment of the 57th embodiment of the first aspect, the monoester of a cholesterol with a dicarboxylic acid is cholesterol hemiglutarate.

[0074] In a 60th embodiment of the first aspect which is also an embodiment of the 57th embodiment of the first aspect, the monoester of a cholesterol with a dicarboxylic acid is cholesterol hemiadipate.

[0075] In a 61st embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th and 55th embodiment of the first aspect, the first lipid is an alkyl carboxylic acid.

[0076] In a 62nd embodiment of the first aspect which is also an embodiment of 61st embodiment of the first aspect, the alkyl carboxylic acid is an alkyl carboxylic acid having 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms.

[0077] In a 63rd embodiment of the first aspect which is also an embodiment of 62nd embodiment of the first aspect, the alkyl carboxylic acid is an alkyl carboxylic acid having 14, 15, 16, 17 or 18 C atoms.

[0078] In a 64th of the first aspect which is also an embodiment of 62nd and 63rd embodiment of the first aspect, the alkyl carboxylic acid is a straight carboxyl acid.

[0079] In a 65th of the first aspect which is also an embodiment of each and any one of the 62nd, 63rd and 64th embodiment of the first aspect, the alkyl carboxylic acid is a saturated alkyl carboxylic acid.

[0080] In a 66th of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th and 55th embodiment of the first aspect, the first lipid is an alkenyl carboxylic acid.

[0081] In a 67th of the first aspect which is also an embodiment of 66th embodiment of the first aspect, the alkenyl carboxylic acid is an alkenyl carboxylic acid having 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms.

[0082] In a 68th of the first aspect which is also an embodiment of 67th embodiment of the first aspect, the alkenyl carboxylic acid is an alkenyl carboxylic acid having 14, 15, 16, 17 or 18 C atoms.

[0083] In a 69th of the first aspect which is also an embodiment of each and any one of the 66th, 67th and 68th embodiment of the first aspect, the alkenyl carboxylic acid is a straight carboxyl acid.

[0084] In a 70th of the first aspect which is also an embodiment of each and any one of the 66th, 67th, 68th and 69th embodiment of the first aspect, the alkenyl carboxylic acid is an unsaturated alkyl carboxylic acid, preferably the alkenyl carboxylic acid has one, two or three double bonds.

[0085] In a 71st embodiment of the first aspect which is also an embodiment of the 70th embodiment of the first aspect, at least one double bond is in the cis configuration.

[0086] In a 72nd embodiment of the first aspect which is also an embodiment of the 71st embodiment of the first aspect, all of the double bonds are in the cis configuration.

[0087] In a 73rd embodiment of the first aspect which is also an embodiment of each and any one of the 66th, 67th, 68th, 69th, 70th, 71st and 72nd embodiment of the first aspect, the alkenyl carboxylic acid is selected from the group consisting of oleic acid, linoleic acid and linolenic acid.

[0088] In a 74th embodiment of the first aspect which is also an embodiment of each and any one of the 66th, 67th, 68th, 69th, 70th, 71st, 72nd and 73rd embodiment of the first aspect, the alkenyl carboxylic acid is oleic acid.

[0089] In a 75th embodiment of the first aspect which is also an embodiment of each and any one of the 66th, 67th, 68th, 69th, 70th, 71st, 72nd and 73rd embodiment of the first aspect, the alkenyl carboxylic acid is linoleic acid.

[0090] In a 76th embodiment of the first aspect which is also an embodiment of each and any one of the 66th, 67th, 68th, 69th, 70th, 71st, 72nd and 73rd embodiment of the first aspect, the alkenyl carboxylic acid is linolenic acid.

[0091] In a 77th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th,

51st, 52nd, 53rd, 54th and 55th embodiment of the first aspect, the first lipid is a monoester of a diacyl glycerol ester with a dicarboxylic acid.

[0092] In a 78th embodiment of the first aspect which is also an embodiment of the 77th embodiment of the first aspect, the dicarboxylic acid of the monoester of a diacyl glycerol ester with a dicarboxylic acid is selected from the group consisting of succinic acid, glutaric acid and adipic acid.

[0093] In a 79th embodiment of the first aspect which is also an embodiment of the 78th embodiment of the first aspect, the monoester of a diacyl glycerol ester with a dicarboxylic acid is a diacyl glycerol hemisuccinat.

[0094] In an 80th embodiment of the first aspect which is also an embodiment of the 78th embodiment of the first aspect, the monoester of a diacyl glycerol ester with a dicarboxylic acid is a diacyl glycerol hemiglutarate.

[0095] In an 81st embodiment of the first aspect which is also an embodiment of the 78th embodiment of the first aspect, the monoester of a diacyl glycerol ester with a dicarboxylic acid is a diacyl glycerol hemiadipate.

[0096] In an 82nd embodiment of the first aspect which is also an embodiment of each and any one of the 77th, 78th, 79th, 80th and 81st embodiment of the first aspect, preferably of the 79th embodiment of the first aspect, each acyl group of the diacyl glycerol is each and independently a residue of a carboxylic acid, wherein the carboxylic acid is each and individually a carboxylic acid having 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms.

[0097] In an 83rd embodiment of the first aspect which is also an embodiment of each and any one of the 77th, 78th, 79th, 80th, 81st and 82nd embodiment of the first aspect, preferably of the 79th embodiment of the first aspect, each acyl group of the diacyl glycerol is each and independently a residue of a carboxylic acid, wherein the carboxylic acid is each and individually a carboxylic acid having 14, 15, 16, 17 or 18 C atoms.

[0098] In an 84th embodiment of the first aspect which is also an embodiment of each and any one of the 77th, 78th, 79th, 80th, 81st, 82nd and 83rd embodiment of the first aspect, preferably of any one of the 79th and 82nd and 83rd embodiment of the first aspect, at least one of the acyl

groups of the diacyl glycerol is a residue of a carboxylic acid, wherein the carboxylic acid is a straight carboxylic acid.

[0099] In an 85th embodiment of the first aspect which is also an embodiment of each and any one of the 77th, 78th, 79th, 80th, 81st, 82nd, 83rd and 84th embodiment of the first aspect, preferably of any one of the 79th and 82nd, 83rd and 84th embodiment of the first aspect, at least one of the acyl groups of the diacyl glycerol is a residue of a carboxylic acid, wherein the carboxylic acid is a saturated carboxylic acid.

[00100] In an 86th embodiment of the first aspect which is also an embodiment of each and any one of the 77th, 78th, 79th, 80th, 81st, 82nd, 83rd and 84th embodiment of the first aspect, preferably of any one of the 79th and 82nd, 83rd and 84th embodiment of the first aspect, at least one of the acyl groups of the diacyl glycerol is a residue of a carboxylic acid, wherein the carboxylic acid is an unsaturated carboxylic acid.

[00101] In an 87th embodiment of the first aspect which is also an embodiment of the each and any one of the 86th embodiment of the first aspect, the unsaturated carboxylic acid has at least one double bond.

[00102] In an 88th embodiment of the first aspect which is also an embodiment of the each and any one of the 86th and the 87th embodiment of the first aspect, the unsaturated carboxylic acid has one, two or three double bonds.

[00103] In an 89th embodiment of the first aspect which is also an embodiment of the each and any one of the 86th, 87th and 88th embodiment of the first aspect, at least one double bond is in the cis configuration.

[00104] In a 90th embodiment of the first aspect which is also an embodiment of the each and any one of the 87th, 88th and 89th embodiment of the first aspect, all of the double bonds are in the cis configuration.

[00105] In a 91st embodiment of the first aspect which is also an embodiment of the each and any one of the 87th, 88th, 89th and 90th embodiment of the first aspect, the unsaturated carboxylic acid is selected from the group consisting of oleic acid, linoleic acid and linolenic acid.

[00106] In a 92nd embodiment of the first aspect which is also an embodiment of the 91st embodiment of the first aspect, the unsaturated carboxylic acid is oleic acid.

[00107] In a 93rd embodiment of the first aspect which is also an embodiment of the 91st embodiment of the first aspect, the unsaturated carboxylic acid is linoleic acid.

[00108] In a 94th embodiment of the first aspect which is also an embodiment of the 91st embodiment of the first aspect, the unsaturated carboxylic acid is linolenic acid.

[00109] In a 95th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th and 55th embodiment of the first aspect, the first lipid is a diacyl-phosphatidyl ester with an alcohol, wherein the alcohol is bearing at least one negative charge at a neutral pH value.

[00110] In a 96th embodiment of the first aspect which is also an embodiment of the 95th embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably a pH value of about 6.0 to about 7.6, more preferably a pH value of about 7.2 to about 7.5, more preferably a pH value of about 7.4.

[00111] In a 97th embodiment of the first aspect which is also an embodiment of the 95th and the 96th embodiment of the first aspect, the alcohol is selected from the group consisting of an OH bearing amino acid and an OH bearing alcohol., preferably the OH bearing alcohol is a OH bearing carboxylic acid.

[00112] In a 98th embodiment of the first aspect which is also an embodiment of the 97th embodiment of the first aspect, the OH bearing amino acid is an α -amino acid.

[00113] In a 99th embodiment of the first aspect which is also an embodiment of the 97th of the first aspect, the OH bearing amino acid is an L-amino acid.

[00114] In a 100th embodiment of the first aspect which is also an embodiment of the 97th of the first aspect, the OH bearing amino acid is an L- α -amino acid.

[00115] In a 101st embodiment of the first aspect which is also an embodiment of each and any one of the 97th, 98th, 99th and 100th embodiment of the first aspect, the OH bearing amino acid is selected from the group consisting of serine and threonine.

[00116] In a 102nd embodiment of the first aspect which is also an embodiment of each and any one of the 97th, 98th, 99th and 100th embodiment of the first aspect, the first lipid is a diacyl-phosphatidylserine.

[00117] In a 103rd embodiment of the first aspect which is also an embodiment of each and any one of the 95th, 96th, 97th, 98th, 99th, 100th, 101st and 102nd embodiment of the first aspect, preferably of the 102nd embodiment of the first aspect, each acyl group of the diacyl-phosphatidyl ester with an alcohol is each and independently a residue of a carboxylic acid, wherein the carboxylic acid is each and individually a carboxylic acid having 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms.

[00118] In a 104th embodiment of the first aspect which is also an embodiment of each and any one of the 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd and 103rd embodiment of the first aspect, preferably of the 102nd and the 103rd embodiment of the first aspect, each acyl group of the diacyl-phosphatidyl ester with an alcohol is each and independently a residue of a carboxylic acid, wherein the carboxylic acid is each and individually a carboxylic acid having 14, 15, 16, 17 or 18 C atoms.

[00119] In a 105th embodiment of the first aspect which is also an embodiment of each and any one of the 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd and 104th embodiment of the first aspect, preferably of the 102nd, 103rd and 104th embodiment of the first aspect, at least one of the acyl groups of the diacyl-phosphatidyl ester with an alcohol is a residue of a carboxylic acid, wherein the carboxylic acid is a straight carboxylic acid.

[00120] In a 106th embodiment of the first aspect which is also an embodiment of each and any one of the 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th and 105th embodiment of the first aspect, preferably of the 102nd, 103rd, 104th and 105th embodiment of the first aspect, at least one of the acyl groups of the diacyl-phosphatidyl ester with an alcohol is a residue of a carboxylic acid, wherein the carboxylic acid is a saturated carboxylic acid.

[00121] In a 107th embodiment of the first aspect which is also an embodiment of each and any one of the 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th and 105th embodiment of the first aspect, preferably of the 102nd, 103rd, 104th and 105th embodiment of the first aspect, at least one of the acyl groups of the diacyl-phosphatidyl ester with an alcohol is a residue of a carboxylic acid, wherein the carboxylic acid is an unsaturated carboxylic acid.

[00122] In a 108th embodiment of the first aspect which is also an embodiment of the 107th embodiment of the first aspect, the unsaturated carboxylic acid has at least one double bond.

[00123] In a 109th embodiment of the first aspect which is also an embodiment of the 107th and 108th embodiment of the first aspect, the unsaturated carboxylic acid has one, two or three double bonds.

[00124] In a 110th embodiment of the first aspect which is also an embodiment of the 108th and 109th embodiment of the first aspect, at least one double bond is in the cis configuration.

[00125] In a 111th embodiment of the first aspect which is also an embodiment of the 108th, 109th and 110th embodiment of the first aspect, all of the double bonds are in the cis configuration.

[00126] In a 112th embodiment of the first aspect which is also an embodiment of the 107th, 108th, 109th, 110th and 111th embodiment of the first aspect, the unsaturated carboxylic acid is selected from the group consisting of oleic acid, linoleic acid and linolenic acid.

[00127] In a 113th embodiment of the first aspect which is also an embodiment of the 112th embodiment of the first aspect, the unsaturated carboxylic acid is oleic acid.

[00128] In a 114th embodiment of the first aspect which is also an embodiment of the 112th embodiment of the first aspect, the unsaturated carboxylic acid is linoleic acid.

[00129] In a 115th embodiment of the first aspect which is also an embodiment of the 112th embodiment of the first aspect, the unsaturated carboxylic acid is linolenic acid.

[00130] In a 116th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th and 115th embodiment of the first aspect, preferably of the 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th,

69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th and 115th embodiment of the first aspect, the second lipid is a lipid bearing more than one cationic charge.

[00131] In a 117th embodiment of the first aspect which is also an embodiment of the 116th embodiment of the first aspect, the lipid bearing more than one cationic charge is a lipid bearing two or more cationic charges.

[00132] In a 118th embodiment of the first aspect which is also an embodiment of the 117th embodiment of the first aspect, the lipid bearing more than one cationic charge is a lipid bearing two or three cationic charges.

[00133] In a 119th embodiment of the first aspect which is also an embodiment of the 116th, 117th and 118th embodiment of the first aspect, the cationic charge is bearing more than one cationic charge at a neutral pH value.

[00134] In a 120th embodiment of the first aspect which is also an embodiment of the 119th embodiment of the first aspect, the neutral pH value is a pH value of about 6.7 to about 7.7, preferably a pH value of about 6.0 to about 7.6, more preferably a pH value of about 7.2 to about 7.5, more preferably a pH value of about 7.4.

[00135] In a 121st embodiment of the first aspect which is also an embodiment of the 116th, 117th, 118th, 119th and 120th embodiment of the first aspect, the second lipid is selected from the group consisting of β -(L-Arginyl)-L-2,3-diamino propionic acid-N,N-dialkyl-amide and L-Arginyl- β -alanine-N,N-dialkyl-amide.

[00136] In a 122nd embodiment of the first aspect which is also an embodiment of the 121st embodiment of the first aspect, the second lipid is β -(L-Arginyl)-L-2,3-diamino propionic acid-N,N-dialkyl-amide, wherein the dialkyl comprises a first alkyl and a second alkyl, wherein the first alkyl and the second alkyl are each and independently selected from a saturated alkyl, an unsaturated alkyl, a straight alkyl and a branched alkyl.

[00137] In a 123rd embodiment of the first aspect which is also an embodiment of the 122nd embodiment of the first aspect, the first alkyl and the second alkyl are each and independently

selected from a saturated straight alkyl, an unsaturated straight alkyl, a saturated branched alkyl and an unsaturated branched alkyl.

[00138] In a 124th embodiment of the first aspect which is also an embodiment of the 123rd embodiment of the first aspect, the alkyl has 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms.

[00139] In a 125th embodiment of the first aspect which is also an embodiment of the 123rd and 124th embodiment of the first aspect, the alkyl has 14, 15, 16, 17 or 18 C atoms, preferably alkyl has 16 C atoms or 18 atoms.

[00140] In a 126th embodiment of the first aspect which is also an embodiment of the 123rd, 124th and 125th embodiment of the first aspect, the alkyl is a saturated alkyl.

[00141] In a 127th embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th and 126th embodiment of the first aspect, the alkyl is a saturated straight alkyl.

[00142] In a 128th embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th, 126th and 127th embodiment of the first aspect, the alkyl is palmityl.

[00143] In a 129th embodiment of the first aspect which is also an embodiment of the 123rd, 124th and 125th embodiment of the first aspect, the alkyl is an unsaturated alkyl.

[00144] In a 130th embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th and 129th embodiment of the first aspect, wherein the alkyl is an unsaturated straight alkyl.

[00145] In a 131st embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th, 129th and 130th embodiment of the first aspect, the unsaturated alkyl comprises at least one double bond, preferably the at least one double bond is in a cis configuration.

[00146] In a 132nd embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th, 129th, 130th and 131st embodiment of the first aspect, the alkyl is oleyl.

[00147] In a 133rd embodiment of the first aspect which is also an embodiment of the 123rd, 124th, 125th, 129th, 130th, 131st and 132nd embodiment of the first aspect, one of the first alkyl and the second alkyl is a saturated alkyl, preferably a saturated straight alkyl, and the other one

of the first alkyl and the second alkyl is an unsaturated alkyl, preferably an unsaturated straight alkyl.

[00148] In a 134th embodiment of the first aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd and 133rd embodiment of the first aspect, the second lipid is selected from the group comprising β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide, L-arginyl- β -alanine-N-palmityl-N-oleyl-amide, DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium), DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane), and DC-Cholesterol (3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride).

[00149] In a 135th embodiment of the first aspect which is also an embodiment of the 134th embodiment of the first aspect, DOTAP is (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) or any other salt thereof such as a mesylate, although the chloride salt is preferred.

[00150] In a 136th embodiment of the first aspect which is also an embodiment of the 134th embodiment of the first aspect, DOTMA is 1,2-di-O-octadecenyl-3-trimethylammonium propane as a chloride salt or any other salt thereof such as a mesylate, although the chloride salt is preferred.

[00151] In a 137th embodiment of the first aspect which is also an embodiment of the 134th 58th embodiment of the first aspect, DC-Cholesterol is 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride or any other salt thereof such as a mesylate, although the chloride salt is preferred.

[00152] In a 138th embodiment of the first aspect which is also an embodiment of the 134th embodiment of the first aspect, the second lipid is selected from a group comprising β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide and L-arginyl- β -alanine-N-

palmitoyl-N-oleyl-amide, preferably, the second lipid is β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide.

[00153] In a 139th embodiment of the first aspect which is also an embodiment of the 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th and 138th embodiment of the first aspect, the third lipid is a zwitterionic phospholipid or an uncharged sterol lipid.

[00154] In a 140th embodiment of the first aspect which is also an embodiment of the 139th embodiment of the first aspect, the zwitterionic phospholipid is selected from the group comprising phosphatidyl ethanolamine and phosphatidyl choline.

[00155] In a 141st embodiment of the first aspect which is also an embodiment of the 139th embodiment of the first aspect, the uncharged sterol lipid is selected from the group comprising a zoosterol and a phytosterol.

[00156] In a 142nd embodiment of the first aspect which is also an embodiment of the 139th and the 140th embodiment of the first aspect, the zwitterionic phospholipid is selected from the group comprising DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DLPE (1,2-Lauroyl-sn-glycero-3-phosphoethanolamine), DPhyPE (1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine), DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), and POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine).

[00157] In a 143rd embodiment of the first aspect which is also an embodiment of the 139th embodiment of the first aspect, the uncharged sterol lipid is selected from the group comprising cholesterol and stigmasterol.

[00158] In a 144th embodiment of the first aspect which is also an embodiment of the 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th,

39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd and 143rd embodiment of the first aspect, the fourth lipid is a shielding lipid.

[00159] In a 145th embodiment of the first aspect which is also an embodiment of the 144th embodiment of the first aspect, the shielding lipid is a lipid comprising a moiety selected from the group comprising PEG (polyethylene glycol), HES (hydroxy ethyl starch), PG (polyglycines) and polySarc (poly-sarcosine (poly-N-methylglycine)).

[00160] In a 146th embodiment of the first aspect which is also an embodiment of the 145th embodiment of the first aspect, the shielding lipid is a PEGylated lipid.

[00161] In a 147th embodiment of the first aspect which is also an embodiment of the 146th embodiment of the first aspect, the PEGylated lipid is selected from the group comprising methoxyPEG-DSPE, methoxyPEG-DMPE, methoxyPEG-DMG, methoxyPEG-DPG, methoxyPEG-DSG, methoxyPEG-c-DMA, 2(methoxyPEG)-N,N-dioctadecylacetamide, 2(methoxyPEG)-N,N-ditetradecylacetamide, methoxyPEG-C8-Ceramide, and methoxyPEG-C16-Ceramide.

[00162] In a 148th embodiment of the first aspect which is also an embodiment of any one of the 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th and 147th embodiment of the first aspect, the PEG moiety of the PEGylated lipid has a molecular weight of from about 750 Da to about 5000 Da, preferably from about 1500 Da to about 3000 Da.

[00163] In a 149th embodiment of the first aspect which is also an embodiment of the 148th embodiment of the first aspect, the PEG is a straight PEG or a branched PEG.

[00164] In a 150th embodiment of the first aspect which is also an embodiment of the 149th embodiment of the first aspect, the PEG is a straight PEG.

[00165] In a 151st embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd and 74th embodiment of the first aspect, preferably of the 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th and 150th embodiment of the first aspect, the molar percentages of the lipids of the lipid composition is as follows:

- 20 – 80 mol% of the first lipid
- 20 – 80 mol% of the second lipid
- 10 – 50 mol% of the third lipid, and
- 1 – 10 mol% of the fourth lipid,

wherein the overall lipid content of the lipid composition is 100 mol%.

[00166] In a 152nd embodiment of the first aspect which is also an embodiment of the 151st embodiment of the first aspect, the molar ratio of the lipid composition is as follows:

- 20 – 60 mol% of the first lipid
- 20 – 60 mol% of the second lipid
- 10 – 40 mol% of the third lipid, and

- 1 – 5 mol% of the fourth lipid,

wherein the overall lipid content of the lipid composition is 100 mol%.

[00167] In a 153rd embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th and 76th embodiment of the first aspect, preferably of the 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st and 152nd embodiment of the first aspect, the lipid composition comprises:

- CHEMS as the first lipid,
- β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid,
- cholesterol as the third lipid,
- methoxyPEG2000-DMPE as the fourth lipid.

[00168] In a 154th embodiment of the first aspect which is also an embodiment of the 153rd embodiment of the first aspect, the lipid composition comprises

- 49 mol% of CHEMS as the first lipid,
- 29 mol% of β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid,

- 20 mol% of cholesterol as the third lipid and
- 2 mol% mPEG2000-DMPE as the fourth lipid.

[00169] In a 155th embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th and 76th embodiment of the first aspect, preferably of the 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149th, 150th, 151st, 152nd, 153rd and 154th embodiment of the first aspect, the lipid composition comprises:

- CHEMS as the first lipid
- β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid
- cholesterol as the third lipid and
- methoxyPEG2000-DMPE as the fourth lipid.

[00170] In an 156th embodiment of the first aspect which is also an embodiment of the 155th embodiment of the first aspect, the lipid composition comprises

- 48 mol% of CHEMS as the first lipid
- 29 mol% of β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid
- 18 mol% of cholesterol as the third lipid and

- 5 mol% of methoxyPEG2000-DMPE as the fourth lipid.

[00171] In a 157th embodiment of the first aspect which is also embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st and 152nd embodiment of the first aspect, the lipid composition is dissolved in a water-miscible solvent.

[00172] In an 158th embodiment of the first aspect which is also an embodiment of the 157th embodiment of the first aspect, the solvent is selected from the group comprising ethanol, acetone, 1-butanol, 2-butanol, tert.-butanol, 3-methyl-1-butanol, 2-methyl-1-propanol, 1-propanol, 2-propanol, dimethylsulfoxide, preferably from a group comprising ethanol, tert.-butanol and 1-butanol.

[00173] In an 159th embodiment of the first aspect which is also an embodiment of any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th and 158th embodiment of the first aspect, the mean particle size of the lipid nanoparticles is from about 15 nm to about 400 nm.

[00174] In an 160th embodiment of the first aspect which is also an embodiment of the 159th embodiment of the first aspect, the mean particle size of the lipid nanoparticles is from about 25 nm to about 200 nm.

[00175] In an 161st embodiment of the first aspect which is also an embodiment of any one of the 159th and 160th embodiment of the first aspect, the mean particle size of the lipid nanoparticles is from about 40 nm to about 100 nm.

[00176] In an 162nd embodiment of the first aspect which is also an embodiment of any one of the 159th, 160th and 161st embodiment of the first aspect, the mean particle size of the lipid nanoparticles is determined by means of dynamic light scattering (DLS).

[00177] In an 163rd embodiment of the first aspect which is also an embodiment of each and any one of the 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th, 158th, 159th, 160th, 161st and 162nd embodiment of the first aspect, the lipid nanoparticles have or show a Zeta-potential, wherein the Zeta-potential is from about -20 mV to about +20 mV

[00178] In an 164th embodiment of the first aspect which is also an embodiment of the 163rd embodiment of the first aspect, the Zeta-potential is from about -10 mV to about +10 mV, preferably the Zeta-potential is from about -5 mV to about +5 mV .

[00179] In an 165th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th,

105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th, 158th, 159th, 160th, 161st, 162nd, 163rd and 164th embodiment of the first aspect, the payload molecule is selected from the group comprising a nucleic acid molecule or a polypeptide molecule comprising between 50 to 1000 amino acids and comprising an isoelectric point (pI) of >6.

[00180] In a 166th embodiment of the first aspect which is also an embodiment of the 165th embodiment of the first aspect, the payload molecule is a nucleic acid molecule.

[00181] In a 167th embodiment of the first aspect which is also an embodiment of each and any one of the 165th and 166th embodiment of the first aspect, the nucleic acid is selected from the group comprising a ribonucleic acid molecule, a deoxyribonucleic acid molecule or a combination thereof.

[00182] In a 168th embodiment of the first aspect which is also an embodiment of each and any one of the 165th, 166th and 176th embodiment of the first aspect, wherein the nucleic acid molecule is a single-stranded nucleic acid molecule, a double-stranded nucleic acid molecule or a partially double-stranded nucleic acid molecule.

[00183] In a 169th embodiment of the first aspect which is also an embodiment of each and any one of the 165th, 166th, 167th and 168th embodiment of the first aspect, the nucleic acid comprises from about 15 to about 20000 nucleotides, preferably the nucleic acid molecule comprises from about 21 to about 10000 nucleotides, more preferably the nucleic acid molecule comprises from about 100 to about 8000 nucleotides and most preferably the nucleic acid molecule comprises from about 200 to about 7000 nucleotides.

[00184] In a 170th embodiment of the first aspect which is also an embodiment of each and any one of the 165th, 166th, 167th, 168th and 169th embodiment of the first aspect, the nucleic acid molecule is a functional nucleic acid molecule.

[00185] In a 171st embodiment of the first aspect which is also an embodiment of the 170th embodiment of the first aspect, the functional nucleic acid molecule is selected from the group comprising an mRNA, a Cas (CRISPR associated endonuclease protein)-encoding mRNA, a plasmid-DNA, an ssDNA (single stranded DNA), an Aptamer, a Spiegelmer, an siRNA

molecule, an antisense molecule, an miRNA (micro RNA) molecule, an sgRNA (single guide RNA) molecule, an saRNA (self amplifying RNA) molecule, and a combination thereof.

[00186] In a 172nd embodiment of the first aspect which is also an embodiment of the 165th, 166th, 167th, 168th, 169th, 170th and 171st embodiment of the first aspect, the lipid to nucleic acid mass ratio in the preparation is from 5 to 40, preferably from 10 to 35, even more preferably the lipid to nucleic acid mass ratio in the preparation is from 15 to 30, and most preferably the lipid to nucleic acid mass ratio in the preparation is about 28

[00187] In a 173rd embodiment of the first aspect which is also an embodiment of the 165th, 166th, 167th, 168th, 169th, 170th, 171st and 172nd embodiment of the first aspect, the nucleic acid molecule is contained within the lipid nanoparticles.

[00188] In a 174th embodiment of the first aspect which is also an embodiment of the 165th, 166th, 167th, 168th, 169th, 170th, 171st, 172nd and 173rd embodiment of the first aspect, the lipid to nucleic acid mass ratio in the lipid preparation is from 5 to 40, preferably from 10 to 35, even more preferably the lipid to nucleic acid mass ratio in the lipid preparation is from 15 to 30, and most preferably the lipid to nucleic acid mass ratio in the lipid preparation is about 28.

[00189] In a 175th embodiment of the first aspect which is also an embodiment of the 165th, 166th, 167th, 168th, 169th, 170th, 171st, 172nd, 173rd and 174th embodiment of the first aspect, the lipid to nucleic acid mass ratio in the lipid nanoparticles is from 5 to 40, preferably from 10 to 35, even more preferably the lipid to nucleic acid mass ratio in the lipid nanoparticles is from 15 to 30, and most preferably the lipid to nucleic acid mass ratio in the lipid nanoparticles is about 28

[00190] In a 176th embodiment of the first aspect which is also an embodiment of the 165th embodiment of the first aspect, the payload molecule is a polypeptide molecule comprising between 10 to 1000 amino acid residues, preferably between 50 to 900 amino acid residues and more preferably between 80 and 800 amino acid residues.

[00191] In a 177th embodiment of the first aspect which is also an embodiment of the 165th and 176th of the first aspect, the polypeptide comprises or has an isoelectric point (pI) of >6.

[00192] In a 178th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st,

32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th, 158th, 159th, 160th, 161st, 162nd, 163rd, 164th, 165th, 166th, 167th, 168th, 169th, 170th, 171st, 172nd, 173rd, 174th, 175th and 176th embodiment of the first aspect, the payload molecule is a therapeutically active agent or a precursor thereof.

[00193] In a 179th embodiment of the first aspect which is also an embodiment of each and any one of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th, 158th, 159th, 160th, 161st, 162nd, 163rd, 164th, 165th, 166th, 167th, 168th, 169th, 170th, 171st, 172nd, 173rd, 174th, 175th, 176th, 177th and 178th embodiment of the first aspect, the preparation is suitable for local administration.

[00194] In a 180th embodiment of the first aspect which is also an embodiment of the 179th embodiment of the first aspect, the local administration is intramuscular administration.

[00195] In a 181st embodiment of the first aspect which is also an embodiment of the 179th embodiment of the first aspect, the local administration is subcutaneous administration.

[00196] In a 182nd embodiment of the first aspect which is also an embodiment of the 179th embodiment of the first aspect, the local administration is intradermal administration,

[00197] The problem underlying the present invention is solved in a second aspect, which is also a first embodiment of the second aspect, by the preparation according to the first aspect,

including any embodiment thereof, for use in a method for the treatment and/or prevention of a disease in a subject, wherein the method comprises local administration of a payload molecule to the subject, preferably the method comprises local administration of the preparation.

[00198] In a second embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intramuscular administration.

[00199] In a third embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is subcutaneous administration.

[00200] In a fourth embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intravitreal administration.

[00201] In a fifth embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intrathecal administration.

[00202] In a sixth embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intratumoral administration.

[00203] In a seventh embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intracerebral administration.

[00204] In an eighth embodiment of the second aspect which is also an embodiment of the first embodiment of the second aspect, the local administration is intradermal administration.

[00205] In a ninth embodiment of the second aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh and eighth embodiment of the second aspect, the disease is a disease which can be treated and/or prevented by the payload molecule.

[00206] The problem underlying the present invention is solved in a third aspect by a pharmaceutical composition comprising a preparation as defined in the first aspect of the present invention, including any embodiment thereof, and a pharmaceutically acceptable excipient.

[00207] The problem underlying the present invention is solved in a fourth aspect, which is also a first embodiment of the fourth aspect, by the pharmaceutical composition according to the third aspect, including any embodiment thereof, for use in a method for the treatment and/or prevention of a disease in a subject, wherein the method comprises local administration of a

payload molecule to the subject, preferably the method comprises local administration of the pharmaceutical composition.

[00208] In a second embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intramuscular administration.

[00209] In a third embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is subcutaneous administration.

[00210] In a fourth embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intravitreal administration.

[00211] In a fifth embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intrathecal administration.

[00212] In a sixth embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intratumoral administration.

[00213] In a seventh embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intracerebral administration.

[00214] In an eighth embodiment of the fourth aspect which is also an embodiment of the first embodiment of the fourth aspect, the local administration is intradermal administration.

[00215] In a ninth embodiment of the fourth aspect which is also an embodiment of the first, second, third, fourth, fifth, sixth, seventh and eighth embodiment of the fourth aspect, the disease is a disease which can be treated and/or prevented by the payload molecule.

[00216] The problem underlying the present invention is solved in a 6th aspect by the use of a first lipid in the preparing of a preparation for use according to the second aspect of the present invention, including any embodiment thereof, wherein the first lipid is a first lipid as defined in the first aspect of the present invention, including any embodiment thereof.

[00217] The problem underlying the present invention is solved in a 7th aspect by the use of a second lipid in the preparing of a preparation for use according to the second aspect of the present invention, including any embodiment thereof, wherein the second lipid is a second lipid as defined in the first aspect of the present invention, including any embodiment thereof.

[00218] The problem underlying the present invention is solved in an 8th aspect by the use of a third lipid in the preparing of a preparation for use according to the second aspect of the present invention, including any embodiment thereof, wherein the third lipid is a third lipid as defined in the first aspect of the present invention, including any embodiment thereof.

[00219] The problem underlying the present invention is solved in a 9th aspect by the use of a fourth lipid in the preparing of a preparation for use according to the second aspect of the present invention, including any embodiment thereof, wherein the fourth lipid is a fourth lipid as defined in the first aspect of the present invention, including any embodiment thereof.

[00220] Without wishing to be bound by any theory, the present inventors surprisingly found that compared to strong cationic LNPs and LNPs comprising ionizable cationic lipids used in the prior art for intramuscular, subcutaneous, and intradermal administration of RNA, a lipid composition used in the preparation according to the present invention and, respectively, and LNPs formed by such lipid composition are superior to those strong cationic LNPs and the pH-sensitive cationic LNPs comprising ionizable cationic lipids. The LNPs formed by the lipid composition used in the preparation according to the present invention are also referred to herein as the LNPs of the present invention.

[00221] The mixture of lipids of the present invention is preferably strongly positively charged at lower pH values since the cationic lipids are positively charged at acidic pH values, but the anionic lipids are not charged anymore due to the protonation of their carboxylic groups. These strongly positively charged lipid systems are capable to interact electrostatically with RNAs, to complex RNAs and to form LNPs accordingly. Once the LNPs of the present invention are formed and the pH of the suspension medium is adjusted to a neutral pH value, the cationic lipids at the surface of the LNPs are still positively charged, but at the same time the negative charges of the anionic lipids are regenerated due to the deprotonation of their carboxylic groups whereas the RNAs are still trapped inside the LNP particle. The molar ratios between cationic lipids and anionic lipids in these amphoteric LNP systems are preferably chosen in a way that at neutral pH values the number of cationic charges which are presented by the cationic lipids outweighs the number of the anionic charges which are presented by the anionic lipids. As a result, the LNP surface is decorated with almost the same number of positive and negative charges. Therefore, the resulting LNP surface can be described as overall neutral and in contrast to LNPs comprising ionizable cationic lipids of the prior art, it is not hydrophobic but hydrophilic.

[00222] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a payload molecule is a compound which is active at a target. The activity is preferably an activity selected from the group comprising a biological activity, a chemical activity, a biochemical activity, a physiological activity, a pharmacological activity and a physical activity. As preferably used herein, a biological activity is an activity which causes a biological effect at the target. Preferably such biological effect is an increase or decrease in activity of a protein, a polypeptide or a peptide, wherein the protein or polypeptide is an enzyme, a structural protein, a scaffold protein, transmembrane protein, a channel protein, a secreted protein, a hormone, a mitochondrial protein, a receptor, a ligand, an epitope/ neoepitope/ antigen peptide (qualifying for MHC-I binding as 9-mer, or MHC-II binding as 13-25-mer) (see, e.g., Andreatta M et al., *Bioinformatics* 2016; 32:511-7), or a nucleic acids binding protein. Alternatively, such biological effect is an increase or decrease in activity or half-life of a nucleic acid molecule, or a localization, positioning, processing, transport, or packaging of a nucleic acid molecule. Such nucleic acid may be a deoxyribonucleic acid or a ribonucleic acid (see, e.g. Jurtz V et al., *J Immunol* 2017; 199:3360-8).

[00223] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a target is selected from the group comprising a molecule, a subcellular structure, a cell, a tissue and an organ. Preferably, a target is targeted by the preparation of the present invention. Target function is envisioned to result in a gain-of-function phenotype, if replacement or substitution or supplementation of defective, aberrant, lost or low protein expression in a given cell by target is desired. Target function is also envisioned to result in a loss-of-function phenotype, if inhibition or abrogation of hyperactive, dominant-active, aberrant, or high protein expression in a given cell by target is desired. For example, in muscle cells genetic mutations are intended to be repaired on the DNA level, defective mutant protein variants are replaced (transient forced expression of active protein) or repaired (mRNA exon skipping). Transient forced protein expression is also intended to be secreted, endocytosed and presented extracellularly by any type of antigen-presenting cells, present or attracted at the site of administration.

[00224] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, local administration is an administration selected from the group comprising of intramuscular administration, subcutaneous administration, intravitreal administration, intrathecal administration, intratumoral

administration, intracerebral administration, intramyocardial administration, intracoronary administration and intradermal administration.

[00225] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a lipid which is pH-independently positively charged is a lipid having an overall positive charge irrespective of the pH to which such lipid is exposed, preferably the pH to which such lipid is exposed in any pH of 0 to 14. More preferably, a lipid which is pH-independently positively charged is selected from the group comprising DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) and DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane chloride).

[00226] In an alternative embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, the overall pKa value of the LNP is measured by using the TNS assay (6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt assay). In a first step, a 4x TNS master buffer is prepared consisting of 100 mM citrate, 80 mM sodium phosphate, 80 mM ammonium acetate and 600 mM sodium chloride and a stock solution of 1 mg/ml TNS in a mixture of dimethylformamide and water (2/8 v/v). To make a series of 2x TNS Assay Buffer with different pH values (e.g., ranging from pH 3 to pH 10) for each pH value 20 ml of the 4x TNS master buffer is put into a tube such as a falcon tube, the pH is adjusted with HCl or NaOH to the target pH value and an appropriate amount of water is added to give 40 ml of a 2x TNS Assay Buffer. Subsequently, a working solution of the LNP the pKa of which is to be determined is prepared by adding 8 µl of TNS stock solution (dimethylformamide and water (2/8 v/v)) and 8 µl of a formulation (10 mM TRIS pH 7.5) containing said LNP (lipid concentration 2-8 mg/ml) to 2 ml water. The measurement is done in a black 96-well plate. For such purpose, 100 µl 2x TNS Assay Buffer per pH value is put in each well and 100 µl of the working solution is added to each well to give a final volume of 200 µl per well. The thus obtained final mixtures are incubated for 30 min at 37 °C and afterwards centrifuged for 1 min at 1000 rpm. The fluorescence intensity of the supernatant is read on a plate reader such as an Tecan M1000 plate reader at an excitation of 322 nm and an emission of 431 nm. After the measurement, the background fluorescence value of an empty well on the 96 well plate is subtracted from each probe /lipid /buffer mixture. The fluorescence intensity values are then normalized to the value at lowest pH. The normalized fluorescence intensity is subsequently plotted against pH and a line of best fit is provided. The point on the line of best fit at which the normalized fluorescence intensity is equal to 0.5 is determined and the corresponding pH value is considered the pKa of the LNP.

[00227] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, an amphoteric overall neutrally charged lipid nanoparticle is a lipid nanoparticle where the sum of negative and positive charges born by the lipid nanoparticle is zero. Preferably the sum is zero if the lipid nanoparticle is exposed to a pH value of 7 to 8, more preferably the lipid particle is exposed to a pH value of 7.4. Consequently, the Zeta-potential of said lipid nanoparticle is zero ± 5 mV.

[00228] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a straight and/or branched chain C1-C4 hydrocarbon group means each and individually any of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl and *tert*-butyl.

[00229] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a neutral lipid is a lipid bearing either no charged molecular moiety or is a zwitterionic lipid molecule comprising the same amount of positively and negatively charged molecular moieties. Preferably the neutral lipid is a sterol or a phosphatidylethanolamine or a phosphatidylcholine.

[00230] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a PEGlyated lipid is a compound comprising a lipid moiety and a PEG moiety attached to the lipid moiety. Preferably, the PEG moiety is covalently attached to the lipid moiety. The lipid moiety is preferably a sterol or a phosphatidylethanolamine or a diacylglycerol and more preferably the lipid moiety is selected from a group comprising 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphatidylethanolamine, 1,2-distearoyl-rac-glycerol, 1,2-dipalmitoyl-rac-glycerol and 1,2-dimyristoyl-rac-glycerol.

[00231] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, an outer surface of a lipid nanoparticle is a surface of a lipid nanoparticle which is facing any medium surrounding the lipid nanoparticle. Preferably, an outer surface of a lipid nanoparticle is opposite to an inner structure of a lipid nanoparticle.

[00232] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a neutral pH value is a pH value of about 6.7 to about 7.7, preferably of about 6.9 to about 7.5, more preferably of about 7.2 to about 7.5.

[00233] In an embodiment of each and any aspect of the present invention including any embodiment thereof a negative charge of the lipid composition is provided by the first lipid.

[00234] In an embodiment of each and any aspect of the present invention including any embodiment thereof a positive charge of the lipid composition is provided by the second lipid.

[00235] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the carboxylic group of the first lipid is present in a protonated or a deprotonated form. If present in the deprotonated form, the carboxylic group confers a negative charge to the first lipid.

[00236] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the pKa value of the first lipid is determined by the carboxylic group group of the first lipid. Preferably, the pKa value of the first lipid is determined by the pKa value of the carboxylic group. More preferably, the pKa value of the carboxylic group is the pKa value of the first lipid.

[00237] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the functional group of the second lipid is present in a protonated or non-protonated form. If present in the protonated form, the functional group confers a positive charge to the second lipid.


[00238] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the second lipid is (a) a cationic lipid having at least one molecular moiety with a pKa value between greater 9.5 and 13.5, or (b) a cationic lipid which is pH-independently positively charged.

[00239] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, the term alkyl group of 12 to 20 hydrocarbons comprises an alkyl group of 12 hydrocarbons, an alkyl group of 13 hydrocarbons, an alkyl group of 14 hydrocarbons, an alkyl group of 15 hydrocarbons, an alkyl group of 16 hydrocarbons, an alkyl group of 17 hydrocarbons, an alkyl group of 18 hydrocarbons, an alkyl group of 19 hydrocarbons and an alkyl group of 20 hydrocarbons.


[00240] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, the term branched alkyl group is an alkyl group having a backbone of hydrocarbon atoms, wherein at least one further hydrocarbon is covalently attached to a carbon atom of the hydrocarbons of the backbone at a position different from the hydrocarbon at either end of the backbone.

[00241] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, the term unsaturated alkyl group is an alkyl group comprising at least two hydrocarbons and at least one double bond covalently linking two hydrocarbons. It will be appreciated by a person skilled in the art that an unsaturated alkyl group comprises one or more double bonds. In a preferred embodiment, the unsaturated alkyl group comprises one, two, three or four double bonds. It will also be appreciated by a person skilled in the art that the double bond can be located at between any two adjacent hydrocarbons of the alkyl group. Preferably, in case the unsaturated alkyl group comprises two or more double bonds, such double bonds are arranged as double bonds separated by two single bonds. It will also be appreciated by a person skilled in the art that the double bond is either a cis double bond or a trans double bond. Preferably the double bond is a cis configured double bond.


[00242] In an embodiment of each and any aspect of the present invention including any embodiment thereof, compound CHEMS (Cholesterol hemisuccinate) is of the following formula:



Preferably the stereocenters are defined as shown in the following formula:




[00243] In an embodiment of each and any aspect of the present invention including any embodiment thereof, compound Alkyl carboxylic acids is of the following formula:




wherein n is = 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

[00244] In an embodiment of each and any aspect of the present invention including any embodiment thereof, compound Diacyl glycerol hemisuccinates is of the following formula:




wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

[00245] In an embodiment of each and any aspect of the present invention including any embodiment thereof, compound Phosphatidylserines is of the following formula:




wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

Preferably the stereocenters are defined as shown in the following formula:




wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.


[00246] In an embodiment of each and any aspect of the present invention including an embodiment thereof, β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00247] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound L-arginyl- β -alanine-N-palmitoyl-N-oleyl-amide is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00248] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-chloride) is of the following formula:




[00249] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DOTMA (1,2-Di-O-octadecenyl-3-trimethylammonium propane (preferably as chloride salt)) is of the following formula:



[00250] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DC-cholesterol (3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride) is of the following formula:



Preferably the stereocenters are defined as shown in the following formula:




[00251] In an embodiment of each and any aspect of the present invention including an embodiment thereof and as preferably used herein a zoosterol is an animal derived sterol.

[00252] In an embodiment of each and any aspect of the present invention including an embodiment thereof and as preferably used herein, a phytosterol is a plant derived sterol.


[00253] In an embodiment of each and any aspect of the present invention including an embodiment thereof and as preferably used herein, a zwitterionic phospholipid is a

phospholipid which comprises an equal number of positively and negatively charged functional groups.

[00254] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DSPC (1,2-Distearoyl-sn-glycero-3-phosphoethanolcholine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00255] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:


[00256]




Preferably the stereocenters are defined as shown in the following formula:




[00257] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DSPE (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00258] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DMPE (1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00259] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DLPE (1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00260] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DPhyPE (1,2-(7R,11R) Diphytanoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00261] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00262] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound POPE ((1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00263] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound cholesterol is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:



[00264] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound Stigmasterol (Stigmasta-5,22-dien-3-ol) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00265] In an embodiment of each and any aspect of the present invention including an embodiment thereof and as preferably used herein, a shielding lipid is a lipid which provides steric stabilization of the lipid nanoparticles and also provides *in vivo* for a reduction of unintended interactions of the lipid nanoparticle surface with proteinaceous body fluids which may otherwise cause aggregation or decomposition of the LNPs. Consequently, it allows for a sustained *in vivo* delivery of the lipid nanoparticle payload to the target cells and thus for a more efficient delivery and prolonged functional bio-activity of the LNP payload. The term shielding also means that elements of the immune system or other defense or removal mechanisms of the body into which such lipid composition is administered, do not immediately interact with the lipid composition again increasing its functional bioavailability in a living organism. Insofar, the shielding lipid acts as an anti-opsonizing compound. Without wishing to be bound by any mechanism or theory, it seems that the shielding lipid forms a cover or coat which reduces the surface area of the lipid composition available for interaction with its environment which would otherwise result in the lipid composition to fuse with other lipids or being bound by factors of the human and animal body, respectively, at a time which is too early for such interaction although it has to be acknowledged that at a later stage, i. e. after a prolonged time upon administration of the lipid composition, such interaction is usually preferred or desired at least to a certain extent so as to provide the delivery of the payload of the lipid composition and preparation of the present invention, respectively.

[00266] The shielding compound is preferably a biologically inert molecular moiety covalently bound to a lipidic moiety. Depending on the hydrophobicity of the lipidic moiety, e.g. the alkyl chain length of the lipidic moiety ranging from C12 to C18 carbons, i.e. 12, 13, 14, 15, 16, 17, 18, 19 and 20 hydrocarbons, the shielding compound can be designed in a way, that it is able to dissociate from the lipid nanoparticle over time, rendering the nanoparticle surface more accessible for intended interactions with membranes of the target cells.

[00267] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-500-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-500] is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00268] Preferably, compound mPEG-500-DSPE is present and used, respectively, as ammonium salt.

[00269] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-1000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00270] Preferably, compound mPEG-1000-DSPE is present and used, respectively, as ammonium salt.

[00271] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00272] Preferably, compound mPEG-2000-DSPE is present and used, respectively, as ammonium salt.

[00273] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-5000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00274] Preferably, compound mPEG-5000-DSPE is present and used, respectively, as ammonium salt.

[00275] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00276] Preferably, compound mPEG-DSPE is present and used, respectively, as ammonium salt.

[00277] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:




[00278] Preferably, compound mPEG-2000-DMPE is present and used, respectively, as ammonium salt.


[00279] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-DMG (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000) is of the following formula:




[00280] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-DPG (1,2-dipalmitoyl-rac-glycero-3-methoxypolyethylene glycol-2000) is of the following formula:




[00281] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-DSG (1,2-dipalmitoyl-rac-glycero-3-methoxypolyethylene glycol-2000) is of the following formula:




In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-C-DMA (N-[(methoxy poly(ethylene glycol)2000)carbamyl]-1,2-dimyristyloxypropyl-3-amine) is of the following formula:




[00282] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound 2-(methoxyPEG-2000)-N,N-dioctadecylacetamide is of the following formula:




[00283] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound 2-(methoxyPEG-2000)-N,N-ditetradecylacetamide is of the following formula:




[00284] In an embodiment of each and any aspect of the present invention including an embodiment thereof, compound mPEG-2000-C8-Ceramide (N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}) is of the following formula:




Preferably the stereocenters are defined as shown in the following formula:



[00285] In an embodiment of each and any aspect of the present invention including any embodiment thereof, compound mPEG-2000-C16-Ceramide (N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}) is of the following formula:



Preferably the stereocenters are defined as shown in the following formula:



[00286] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the mean particle size of the lipid nanoparticles is determined by means of dynamic light scattering (DLS) using a Zetasizer Ultra (Malvern Panalytical Ltd, Malvern, UK). All measurements are preferably carried out in an aqueous buffer as dispersant, which is a 270 mM sucrose solution buffered with 10 mM TRIS at pH 7.4. DLS is, for example, disclosed in more detail in Stetefeld, J., McKenna, S. A. & Patel, T. R. “Dynamic light scattering: a practical guide and applications in biomedical sciences”. Biophys Rev 8, 409–427 (2016); and Thomas, J. C. “The determination of log normal particle size distributions by dynamic light scattering”. Journal of Colloid and Interface Science 117, 187–192 (1987); the disclosure of which is herein incorporated by reference.

[00287] In an embodiment of each and any aspect of the present invention including any embodiment thereof, a zeta-potential such as a zeta-potential of lipid nanoparticles is measured by Laser Doppler Electrophoresis using a Zetasizer Ultra (Malvern Panalytical Ltd, Malvern, UK). All measurements are preferably carried out in an aqueous buffer as dispersant, which is a 270 mM sucrose solution buffered with 10 mM TRIS at pH 7.4. Laser Doppler Electrophoresis is, for example, described in more detail in Clogston, J. D. & Patri, A. K. in “Characterization of Nanoparticles Intended for Drug Delivery” 697, 63–70 (Humana Press, 2011); and Sze, A., Erickson, D., Ren, L. & Li, D. “Zeta-potential measurement using the Smoluchowski equation and the slope of the current–time relationship in electroosmotic flow”, Journal of Colloid and Interface Science 261, 402–410 (2003), the disclosure of which is incorporated herein by reference.

[00288] In an embodiment of each and any aspect of the present invention including any embodiment thereof, the overall charge of the lipid nanoparticles is about ± 10 mV, preferably about ± 5 mV.

[00289] It will be appreciated by a person skilled in the art that the zeta potential of lipid nanoparticles is reflecting the overall charge of such lipid nanoparticles.

[00290] In an embodiment of each and any aspect of the present invention including any embodiment thereof, a nucleic acid molecule is a polymer of building blocks. Said building blocks are nucleotides. In an embodiment of each and any aspect of the present invention including any embodiment thereof, a ribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are ribonucleotides. In an embodiment of each and any aspect of the present invention including any embodiment thereof, a deoxyribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are deoxyribonucleotides, preferably 2' deoxyribonucleotides. In an embodiment of each and any aspect of the present invention including any embodiment thereof, said nucleotide building blocks are selected from a group comprising 2'-fluoro, 2'-methoxy modified ribonucleotides.

[00291] In an embodiment of each and any aspect of the present invention, including any embodiment thereof, a nucleic acid molecule is a D-nucleic acid molecule. In an embodiment and as preferably used herein, a D-nucleic acid molecule is a polymer of building blocks, wherein said building blocks are D-nucleotides. In a preferred embodiment of each and any aspect of the present invention including any embodiment thereof, a D-nucleic acid molecule is a D-ribonucleic acid molecule. In an embodiment and as preferably used herein, a D-

ribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are D-ribonucleotides. In an alternative preferred embodiment of each and any aspect of the present invention including any embodiment thereof, a D-nucleic acid molecule is a D-deoxyribonucleic acid molecule. In an embodiment and as preferably used herein, a D-deoxyribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are D-deoxyribonucleotides.

[00292] In an embodiment of each and any aspect of the present invention including any embodiment thereof, a nucleic acid molecule is a D,L-nucleic acid molecule. In an embodiment and as preferably used herein, a D,L-nucleic acid molecule is a polymer of building blocks, wherein said building blocks are both D-nucleotides and L-nucleotides. It will be appreciated by a person skilled in the art that any relative ratio of D-nucleotides to L-nucleotides may be realized in such D,L-nucleic acid molecule. It will be further appreciated by a person skilled in the art that any arrangement of said D-nucleotides and L-nucleotides may be realized in such D,L-nucleic acid molecule. In a preferred embodiment of each and any aspect of the present invention including any embodiment thereof, a D,L-nucleic acid molecule is a D,L-ribonucleic acid molecule. In an embodiment and as preferably used herein, a D,L-ribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are both D-ribonucleotides and L-ribonucleotides. In an alternative preferred embodiment of each and any aspect of the present invention including any embodiment thereof, a D,L-nucleic acid molecule is a D, L-deoxyribonucleic acid molecule. In an embodiment and as preferably used herein, a D,L-deoxyribonucleic acid molecule is a polymer of building blocks, wherein said building blocks are both D-deoxyribonucleotides and L-deoxyribonucleotides.

[00293] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a single-stranded nucleic acid molecule is a nucleic acid molecule which consists of a single strand of nucleotides covalently attached to each other, preferably by means of a bond or linkage selected from the group consisting of a phosphodiester bond or a phosphothioether linkage. Preferably such linkage covalently links the OH group of a 3' C atom of a sugar moiety of a first nucleoside to a first OH group of a phosphate and the OH group of a 5' C atom of a sugar moiety of a second nucleoside to a second OH group of the phosphate.

[00294] In an embodiment of each and any aspect of the present invention including any embodiment thereof and as preferably used herein, a double-stranded nucleic acid molecule is

a nucleic acid molecule which comprises a double-stranded structure. Said double-stranded structure is a structure where a first strand of nucleotides and a second strand of nucleotides are attached to each other. Such attachment is preferably selected from the group comprising a non-covalent attachment and a covalent attachment. In an embodiment, said non-covalent attachment is an attachment mediated or caused by one or more hydrogen bonds; preferably said non-covalent attachment is mediated or caused by Watson-Crick base pairing or by Hoogsteen base pairing between one or more of the nucleotides forming the first stand of nucleotides and the second strand of nucleotides. More preferably, all of the nucleotides of the first strand of nucleotides and all of the nucleotides of the second strand of nucleotides are involved in such base pairing, whereby one nucleotide of the first strand is base-pairing with one nucleotide of the second strand.

[00295] In an alternative embodiment, said covalent attachment is an attachment mediated by one or more covalent bonds between at least one nucleotide of the first strand of nucleotides forming the double-stranded structure and at least one nucleotide of the second strand of nucleotide forming the double-strand.

[00296] In an embodiment and as preferably used herein a functional nucleic acid molecule is a nucleic acid molecule having a function different from a structural nucleic acid molecule. In a preferred embodiment, a functional nucleic acid molecule is different from a ribosomal ribonucleic acid molecule, and different from a 7SL-RNA, and different from a ribozyme

[00297] In an embodiment and as preferably used herein, an mRNA is a nucleic acid molecule comprising 5' -> 3' direction, a Cap structure, a 5' untranslated region (5' UTR), a coding sequence typically starting with an AUG codon attached to a coding sequence (CDS) terminating with a stop codon, a 3' untranslated region (3' UTR) and a poly-A-tail. Preferably, the mRNA is made of ribonucleotides, more preferably of D-ribonucleotides.

[00298] In an embodiment and as preferably used herein, a Cas (CRISPR associated endonuclease protein)-encoding mRNA is an mRNA coding for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) associated endonuclease protein. Cas proteins and derivatives thereof include for example Cas9 DNA nuclease (NCBI Reference Sequence (mRNA): NC_002737.2; NCBI Reference Sequence (Prot): NP_269215.1) or Cas13a-d RNA nuclease (e.g. LwaCas13a *Leptotrichia wadeii* (NCBI Reference Sequence: WP_021746003.1); PspCas13b *Prevotella sp. P5-125*; RfxCas13d *Ruminococcus flavefaciens* (NCBI Reference Sequence: WP_075424065.1))

[00299] In an embodiment and as preferably used herein, an aptamer is a single-stranded nucleic acid molecule that can form distinct and stable three-dimensional structures and specifically bind to a target molecule, wherein the aptamer is preferably made of D-nucleotides. Aptamers can be identified against several target molecules, e.g. small molecules, proteins, nucleic acids, and even cells, tissues and organisms and can inhibit the in vitro and/or in vivo function of the specific target molecule. Aptamers are usually identified by a target-directed selection process, called in vitro selection or Systematic Evolution of Ligands by Exponential Enrichment (abbr. SELEX) (Bock L.C. et al. (1992), *Nature*. 355(6360):564-6; Ellington & Szostak (1990) *Nature*, 346(6287):818-22; Tuerk C. and Gold L. (1990), *Science*. 249(4968):505-10). Non-modified aptamers are cleared rapidly from the bloodstream, with a half-life of minutes to hours, mainly due to nuclease degradation and clearance from the body by the kidneys, a result of the aptamer's inherently low molecular weight. Hence, in order to use aptamers therapeutically they have to be modified at the 2' position of the sugar. More preferably the binding of the aptamer to the target molecule is by means of non-covalent bonds, more preferably the by bonds different from Watson-Crick base pairing of Hoogsteen base pairing.

[00300] In an embodiment and as preferably used herein, a spiegelmer is a single-stranded nucleic acid molecule that can form distinct and stable three-dimensional structures and specifically bind to a target molecule, wherein the spiegelmer is preferably made of L-nucleotides. Spiegelmers can be identified against several target molecules, e.g., small molecules, proteins, nucleic acids, and even cells, tissues and organisms and can inhibit the in vitro and/or in vivo function of the specific target molecule. Spiegelmers are identified by a mirror-image selection published first in 1996 (Klussmann S. et al. (1996), *Nat Biotechnol.* 14(9):1112-5; Nolte A. et al. (1996), *Nat Biotechnol.* 14(9):1116-9). More preferably the binding of the aptamer to the target molecule is by means of non-covalent bonds, more preferably the by bonds different from Watson-Crick base pairing of Hoogsteen base pairing.

[00301] In an embodiment and as used herein, a plasmid DNA is a recombinant, circular double-stranded deoxyribonucleic acid molecule, comprising a nucleotide sequence, in particular an open reading frame under the control of a eukaryotic promoter sequence, encoding, e.g., a pharmacologically active polypeptide or protein. Alternatively, the eukaryotic promoter system is used to express a pharmacologically active nucleotide sequence encoding, a long non-coding RNA, a tRNA and/or an shRNA/ siRNA.

[00302] In an embodiment and as preferably used herein, an siRNA which is also referred to as short interfering RNA or silencing RNA in the art, is a class of double-stranded RNA non-coding RNA molecules, typically 20-24 base pairs in length and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. siRNA molecules may be catalytically produced by the Dicer Enzyme from long double-stranded and small hairpin RNA molecules. The siRNA-induced post transcriptional gene silencing starts with the assembly of the RNA-induced silencing complex (RISC). The complex silences certain gene expression by cleaving the mRNA molecules coding the target genes. To begin the process, one of the two siRNA strands, the guide strand (anti-sense strand), will be loaded into the RISC while the other strand, the passenger strand (sense strand), is degraded. Certain Dicer enzymes may be responsible for loading the guide strand into RISC. Then, the siRNA scans for and directs RISC to – essentially - perfectly complementary sequence on the mRNA molecules. The cleavage of the mRNA molecules is thought to be catalyzed by the Piwi domain of Argonaute proteins of the RISC. The mRNA molecule is then cut precisely by cleaving the phosphodiester bond between the target nucleotides which are paired to siRNA residues 10 and 11, counting from the 5' end. This cleavage results in mRNA fragments that are further degraded by cellular exonucleases. The 5' fragment is degraded from its 3' end by exosome while the 3' fragment is degraded from its 5' end by 5' -3' exoribonuclease 1 (XRN1). Dissociation of the target mRNA strand from RISC after the cleavage allow more mRNA to be silenced. This dissociation process is likely to be promoted by extrinsic factors driven by ATP hydrolysis. Alternatively, siRNAs can be incorporated into an RNA-induced transcriptional silencing (RITS) complex. An active RITS complex will trigger the formation of heterochromatin around DNA matching the siRNA, effectively silencing the genes in that region of the DNA.

[00303] In an embodiment and as preferably used herein, an antisense molecule or antisense oligonucleotide is a single-stranded deoxyribonucleic acid or a single-stranded- ribonucleic acid.

[00304] In an embodiment and as preferably used herein, a natural or synthetic microRNA (miRNA, antagomir) is a small single-stranded non-coding RNA molecule containing about 22 nucleotides, that functions in gene silencing by post-transcriptional regulation of mRNA expression. miRNAs function via base-pairing with complementary sequences within mRNA molecules. As a result, these mRNA molecules are silenced, by one or more of the following

processes: (1) cleavage of the mRNA strand into two pieces, (2) destabilization of the mRNA through shortening of its poly(A) tail and mRNA decay, and (3) by blocking mRNA translation.

[00305] In an embodiment and as preferably used herein, a single guide RNA (sgRNA) is a specific RNA sequence that recognizes the target DNA region of interest and directs a Cas nuclease there for editing. The sgRNA is made up of two parts: crRNA, a nucleotide sequence of 17, 18, 19 or 20 nucleotides complementary to the target DNA, and a tracrRNA, which serves as a binding scaffold for the Cas nuclease. A sgRNA is a version of the naturally occurring two-piece guide RNA complex engineered into a single, continuous sequence. The simplified single-guide RNA is used to direct the Cas9 protein to bind and cleave a particular DNA sequence for genome editing.

[00306] In an embodiment and as preferably used herein, a self-amplifying RNA (saRNA) is encoding 5' and 3' CSE sequences, the Alphavirus nsP1-4 genes, a subgenomic promoter, and the protein coding region of a therapeutic protein or antigen. Following in situ translation, the nsP1-4 proteins form an RdRP complex which recognizes flanking CSE sequences and amplifies protein-encoding transcripts.

[00307] In an embodiment and as preferably used herein the lipid to nucleic acid mass ratio is the ratio of [the mass of the lipid composition of the preparation] to [the mass of the nucleic acid of the preparation]. More preferably, the mass of the nucleic acid of the preparation is the mass of the total of the nucleic acid molecules contained in the preparation.

[00308] In an embodiment and as preferably used herein, the nucleic acid molecule is contained within the lipid nanoparticles. It will be understood by a person skilled in the art that the term "contained within the lipid nanoparticles" preferably means that the majority of the individual nucleic acid molecules contained in the preparation is contained within the lipid nanoparticles. It is, however, also within the present invention that the individual nucleic acid molecules are, at least to a certain percentage, attached to the lipid nanoparticles. It is also within the present invention that the majority of the individual nucleic acid molecules are associated with the lipid composition of the preparation comprising a payload molecule and a lipid composition with the payload molecule and the lipid composition preferably being the one disclosed herein. It will be equally understood by a person skilled in the art that the disclosure specifically presented herein related to a nucleic acid molecule as a payload of the preparation equally applies to a polypeptide as a payload of the preparation.

[00309] In an embodiment and as preferably used herein, intramuscular administration is the injection of a substance into a muscle (e.g., striated muscle and smooth muscle, skeletal and cardiac muscle, sphincter muscles). It is one of several methods for parenteral administration of medications. Intramuscular injection may be preferred because muscles have larger and more numerous blood vessels than subcutaneous tissue, leading to faster absorption than subcutaneous or intradermal injections. Medication administered via intramuscular injection is not subject to the first-pass metabolism effect which affects oral medications.

[00310] Common sites for intramuscular injections include the deltoid muscle of the upper arm and the gluteal muscle of the buttock. In infants, the vastus lateralis muscle of the thigh is commonly used. Intramuscular administration after injection into skeletal muscle results in the delivery of larger volumes of a substance into the muscle tissue under the dermal and subcutaneous layer. The muscle is connected to the large network of blood and lymph vessels and offers depot effects for the substance and pronounced exposure to antigen presenting cells.

[00311] Subcutaneous administration refers to delivery into the subcutis region under the dermis and epidermis, whereas intradermal administration refers to delivery of the substance to the dermis directly. Both routes also offer depot effects to some extent. Intramyocardial administration refers to direct injections of substances into the cardiac muscle/ myocardium. Furthermore, non-skeletal muscles can be reached by direct injection of the substance into the given tissue, e.g., sphincter muscle of the urinary tract for stress urinary incontinence.

[00312] In an embodiment and as preferably used herein, the disease for the treatment and/or prevention of which the preparation of the invention may be used is a disease which can be treated and/or prevented by the payload molecule. Diseases include, but are not limited to: peripheral arterial disease (mRNA payload: VEGF165/COMP-Ang1, Follistatin-like 1), myositis (mRNA payload: anti-inflammatory cytokines), muscle hypertrophy (mRNA payload: Myostatin), diet-induced obesity (mRNA payload: IL-6, BDNF, FGF21), ischemia-reperfusion injury (mRNA payload: Myonectin), LAMA2-deficient muscular dystrophy (mRNA payload: α LNNd, Mini-agrin), depression (payload: kynurenine aminotransferase) Muscular and neuromuscular disorders comprise diseases such as myopathies, congenital myopathies, mitochondrial myopathies (payload tRNAs), muscular degeneration, muscular dystrophies, myositis, cancer (e.g. soft tissue sarcoma), atrophy (payload mRNA for various growth factors), hypertrophy, pseudohypertrophy, hypotonia, muscular spasms, cachexia, glycogen storage

diseases of muscle, muscle weakness (e.g. Myasthenia gravis) and cardiomyopathies and myocardial infarction.

[00313] In an embodiment and as preferably used herein, the prevention and/or treatment of a disease using a preparation of the underlying invention, comprises vaccination. In the context of the present invention, intramuscular delivery of a payload, such as a protein or an mRNA/ nucleic acid encoding a protein or polypeptide, acting as epitope or neoepitope (antigens) for antigen-presenting cells can be harnessed as vaccine to elicit an antigen specific immune response. Vaccination in the context of the present invention is intended to prevent or treat diseases such as infections, cancer, allergy and autoimmune diseases.

[00314] In an embodiment and as preferably used herein a pharmaceutically acceptable excipient is a pharmaceutically acceptable aqueous buffer system, preferably the buffer system has a physiological pH value and isoosmolar strength and further comprises a cryoprotectant, more preferably the buffer system has a pH value of 7.0 to 7.4 and an osmolality of 250 to 330 mosmol/kg and comprises a cryoprotectant selected from a group comprising sucrose and trehalose, and even more preferably the buffer system is a 10 mM phosphate or 10 mM TRIS/HCl buffer of pH 7.4 and comprises 270 mM Sucrose as cryoprotectant. Other pharmaceutically acceptable excipients are known to the person skilled in the art.

[00315] In an embodiment and as preferably used herein, a subject is a mammal selected from the group comprising human, monkey, rat and mouse, preferably a subject is a human being.

[00316] In an embodiment and as preferably used herein, a payload molecule is a therapeutically active agent.

[00317] In an embodiment and as preferably used herein, therapy is a method for the treatment and/or prevention of a disease in a subject, preferably the method comprises administering to the subject an agent which is suitable for or effective in the treatment and/or prevention of the disease.

[00318] In an embodiment and as preferably used herein, therapy is a method for treating and/or preventing of a disease. More preferably, in such method for treating and/or preventing a disease a therapeutically active agent is administered to a subject, preferably a subject in need of such treatment and/or prevention. In an embodiment thereof, the subject is a human being.

[00319] It will be appreciated by a person skilled in the art that the preparation disclosed herein, preferably the one disclosed for use in therapy, may also be used for diagnosis, preferably in vivo or in situ diagnosis.

[00320] In an embodiment and as preferably used herein, diagnosis is a method for diagnosing a disease. More preferably, in such method for diagnosing a disease a diagnostically active agent is administered to a subject, preferably a subject in need of such diagnosis. In an embodiment thereof, the subject is a human being.

[00321] In an embodiment and as preferably used herein, a monoester of a cholesterol with a dicarboxylic acid is an ester formed between an OH group of the cholesterol and one carboxy group of the dicarboxylic acid. In accordance therewith, a monoester of a cholesterol with a dicarboxylic acid, wherein the dicarboxylic acid is succinic acid, is a cholesterol hemisuccinate; a monoester of a cholesterol with a dicarboxylic acid, wherein the dicarboxylic acid is glutaric acid, is a cholesterol hemiglutarate; and a monoester of a cholesterol with a dicarboxylic acid, wherein the dicarboxylic acid is adipic acid, is a cholesterol hemiadipate.

[00322] In an embodiment and as preferably used herein, if a compound is said to bear a negative charge at an indicated pH value, this means that such compound has a negative charge in a medium, wherein the medium has the indicated pH value. In a preferred embodiment, the medium is a fluid forming the fluid part of the preparation comprising the lipid nanoparticles, wherein the lipid nanoparticles comprise the lipid composition and wherein the lipid composition comprises the first lipid and the second lipid.

[00323] In an embodiment and as preferably used herein, if a compound is said to bear a positive charge at an indicated pH, this means that such compound has a positive charge in a medium, wherein the medium has the indicated pH value. In a preferred embodiment, the medium is a fluid forming the fluid part of the preparation comprising the lipid nanoparticles, wherein the lipid nanoparticles comprise the lipid composition and wherein the lipid composition comprises the first lipid and the second lipid.

[00324] In an embodiment and as preferably used herein, a lipid is a molecule comprising a hydrophobic moiety and a hydrophilic moiety, wherein the hydrophilic moiety is a water attracting chemical group, preferably a chemical group bearing at least one negative or positive charge at a pH of 7.2-7.5.

[00325] The preparation of the present invention, particularly as disclosed in connection with the first aspect, relies on mixing a solution comprising the lipid components of the lipid composition with a solution comprising the mRNA, wherein the mixing is an in-line mixing. The mixing step is performed by the application of a microfluidic mixing device and can particularly either be done by the use of a staggered herringbone mixer device, a Dean Vortex bifurcating mixing device or a microfluidic hydrodynamic mixing device. These devices allow due to their special designed micro channels a rapid, non-turbulent and diffusion based mixing processes. A staggered herringbone mixer and its use in the preparation of particles as preferably contained in the composition of the invention, is, for example, described in Zhigaltsev, I. V. et al. "Bottom-Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride Cores Using Millisecond Microfluidic Mixing". *Langmuir* 28, 3633–3640 (2012), the disclosure of which is incorporated herein by reference. Microfluidic hydrodynamic mixing and its use in the preparation of particles as preferably contained in the composition of the invention, is, for example, described in Krzysztoń, R. et al. "Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles." *Nanoscale* 9, 7442–7453 (2017), the disclosure of which is incorporated herein by reference. Finally, Dean vortex bifurcating mixing and its use in the preparation of particles as preferably contained in the composition of the invention, is, for example, described in Chen, J. J., Chen, C. H. & Shie, S. R. "Optimal designs of staggered dean vortex micromixers." *Int J Mol Sci* 12, 3500–3524 (2011), the disclosure of which is incorporated herein by reference. In addition to the microfluidic mixing procedures, the mixing of a solution comprising the lipid components of the lipid composition with a solution comprising the mRNA can be performed using a confined impingement jet mixer [Knauer GmbH, Berlin, Germany].

[00326] The present invention will be further illustrated by the following examples from which further features, embodiments and advantages may be taken, wherein

Fig. 1 shows the study design for in vivo assessment of luciferase expression after intramuscular injection into mice of FLuc-mRNA, FLuc-mRNA encapsulated into cationic LNP's, FLuc-mRNA encapsulated into overall neutral LNP's according to the present invention and FLuc-mRNA encapsulated into neutral LNP based on ionizable cationic lipids according to the prior art;

Fig. 2 is a diagram showing relative light units as indication of luciferase activity of various formulations, more specifically Fig. 2 shows the obtained luciferase

expression results after intramuscular injection into mice of FLuc-mRNA, FLuc-mRNA encapsulated into cationic LNP's, FLuc-mRNA encapsulated into overall neutral LNP's according to the present invention and FLuc-mRNA encapsulated into neutral LNP based on ionizable cationic lipids according to the prior art;

Fig. 3 shows diagram I indicating a pH-dependent overall surface charge of lipid nanoparticles of an embodiment of the preparation according to the present invention, wherein the first lipid of the lipid composition is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid of the lipid composition is bearing three functional groups which are protonated in a pH-dependent manner;

Fig. 4 shows diagram II indicating a pH-dependent overall surface charge of lipid nanoparticles of an embodiment of the preparation according to the present invention, wherein the first lipid of the lipid composition is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid of the lipid composition is bearing two functional groups which are protonated in a pH-dependent manner; and

Fig. 5 shows diagram III indicating a pH-dependent overall surface charge of lipid nanoparticles of an embodiment of the preparation according to the present invention, wherein the first lipid of the lipid composition is bearing a carboxylic group which is deprotonated in a pH-dependent manner, and the second lipid of the lipid composition is bearing one functional group which is protonated in a pH-dependent manner.

Example 1: Formulation of FLuc mRNA in lipid nanoparticles (PTX_LNP#1) for in vivo applications by intramuscular, subcutaneous or intradermal administration

[00327] For in vivo experiments, mRNA-LNPs were prepared in a formulation process with β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide as cationic lipid. Alternatively, other cationic lipids like L-Arginyl- β -alanine-N-palmityl-N-oleyl-amide can be used in an identical procedure to prepare similar mRNA-LNPs.

[00328] A lipid solution was prepared by dissolving the lipid components 2 β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide: DPhyPE: mPEG-2000-DSPE at a molar ratio of 50:49:1 in ethanol. Subsequently, this lipid solution was mixed with a solution

of CleanCap® FLuc mRNA (5moU (=5-methoxy-uridine modification); Trilink Biotechnologies, San Diego) in water at a volume ratio (RNA solution: lipid solution) of 2:1 using a microfluidic mixer (NanoAssemblr®; Precision Nanosystems, Vancouver, BC), applying an overall flow rate of 18 ml/min. The applied lipid and mRNA concentrations were adjusted in a way, that the total lipid to mRNA mass ratio of the thus obtained mRNA formulation equals 28. After the mixing process, the formulations were dialyzed against 10 mM TRIS buffered 270 mM Sucrose solution using 3.5 kDa MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher Scientific). The formulation in the floating dialysis cassette was dialyzed for 2 hours at room temperature while gently stirring the dialysis buffer; the dialysis buffer was changed and dialyzed for another 2 hours at room temperature. Once again, the dialysis buffer was changed and dialyzed at 4 °C overnight. During the dialysis procedure, a total dialysis buffer of at least 300 times the volume of the sample was used. Instead of Sucrose, other sugars like Trehalose or Glucose can equally be used within the formulation process.

[00329] Subsequently, the thus obtained formulation was tested for particle size (Zetasizer Ultra instrument (Malvern Instruments Ltd, Malvern, UK), RNA encapsulation (Quant-iT RiboGreen RNA Assay Kit following manufacturer's (Thermo Fisher Scientific) protocol, and endotoxin content. Particle sizes were found to be between 60 to 90 nm (Z-Average) having a Zeta-potential of 35 mV +/- 10 mV. The formulation displayed greater than 90 % mRNA encapsulation. At this point, the final mRNA-concentration of the formulation was adjusted to 100 µg/ml. The obtained mRNA-LNP formulations were stored at -80 °C until further in vitro or in vivo use.

Example 2: Formulation of FLuc mRNA in lipid nanoparticles (PTX_LNP#2) for in vivo applications by intramuscular, subcutaneous or intradermal administration

[00330] For in vivo experiments, mRNA-LNPs were prepared in a formulation process with β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide as cationic lipid. Alternatively, other cationic lipids like L-Arginyl- β -alanine-N-palmityl-N-oleyl-amide can be used in an identical procedure to prepare similar mRNA-LNPs.

[00331] A lipid solution was prepared by dissolving the lipid components 2 β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide: Cholesterol: mPEG-2000-DSPE at a

molar ratio of 70:29:1 in ethanol. Subsequently, this lipid solution was mixed with a solution of CleanCap® FLuc mRNA (5moU; Trilink Biotechnologies, San Diego) in water at a volume ratio (RNA solution: lipid solution) of 3:1 using a microfluidic mixer (NanoAssembler®; Precision Nanosystems, Vancouver, BC), applying an overall flow rate of 18 ml/min. The applied lipid and mRNA concentrations were adjusted in a way, that the total lipid to mRNA mass ratio of the thus obtained mRNA formulation equals 14. After the mixing process, the formulations were dialyzed against 10 mM TRIS buffered 270 mM Sucrose solution using 3.5 kDa MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher Scientific). The formulation in the floating dialysis cassette was dialyzed for 2 hours at room temperature while gently stirring the dialysis buffer; the dialysis buffer was changed and dialyzed for another 2 hours at room temperature. Once again, the dialysis buffer was changed and dialyzed at 4 °C overnight. During the dialysis procedure, a total dialysis buffer of at least 300 times the volume of the sample was used. Instead of Sucrose, other sugars like Trehalose or Glucose can equally be used within the formulation process.

[00332] Subsequently, the thus obtained formulation was tested for particle size (Zetasizer Ultra instrument (Malvern Instruments Ltd, Malvern, UK), RNA encapsulation (Quant-iT RiboGreen RNA Assay Kit following manufacturer's (Thermo Fisher Scientific) protocol, and endotoxin content. Particle sizes were found to be between 60 to 90 nm (Z-Average) having a Zeta-potential of 35 mV +/- 10 mV. The formulation displayed greater than 90 % mRNA encapsulation. At this point, the final mRNA-concentration of the formulation was adjusted to 100 µg/ml. The obtained mRNA-LNP formulations were stored at -80 °C until further in vitro or in vivo use.

Example 3: Example 3: Formulation of FLuc mRNA in neutral lipid nanoparticles (PTX_LNP#3) for in vivo applications by intramuscular, subcutaneous or intradermal administration

[00333] For in vivo experiments, mRNA-LNPs were prepared in a formulation process with β-(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide as cationic lipid. Alternatively, other cationic lipids like L-Arginyl-β-alanine-N-palmityl-N-oleyl-amide can be used in an identical procedure to prepare similar mRNA-LNPs.

[00334] A lipid solution was prepared by dissolving the lipid components 2 β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide: CHEMS: Cholesterol: mPEG-2000-DMPE at a molar ratio of 29:49:20:2 in ethanol. Subsequently, this lipid solution was mixed with a solution of CleanCap® FLuc mRNA (5moU; Trilink Biotechnologies, San Diego) in acetate buffer (50 mM, pH 4) at a volume ratio (RNA solution: lipid solution) of 2:1 using a microfluidic mixer (NanoAssemblr®; Precision Nanosystems, Vancouver, BC), applying an overall flow rate of 18 ml/min. The applied lipid and mRNA concentrations were adjusted in a way, that the total lipid to mRNA mass ratio of the thus obtained mRNA formulation equals 28. After the mixing process, the formulations were dialyzed against 10 mM TRIS buffered 270 mM Sucrose solution using 3.5 kDa MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher Scientific). The formulation in the floating dialysis cassette was dialyzed for 2 hours at room temperature while gently stirring the dialysis buffer; the dialysis buffer was changed and dialyzed for another 2 hours at room temperature. Once again, the dialysis buffer was changed and dialyzed at 4 °C overnight. During the dialysis procedure, a total dialysis buffer of at least 300 times the volume of the sample was used. Instead of Sucrose, other sugars like Trehalose or Glucose can equally be used within the formulation process.

[00335] Subsequently, the thus obtained formulation was tested for particle size (Zetasizer Ultra instrument (Malvern Instruments Ltd, Malvern, UK), RNA encapsulation (Quant-iT RiboGreen RNA Assay Kit following manufacturer's (Thermo Fisher Scientific) protocol, and endotoxin content. Particle sizes were found to be between 60 to 90 nm (Z-Average) having a Zeta-potential of 0 mV $\pm$ 10 mV. The formulation displays greater than 90 % mRNA encapsulation. At this point, the final mRNA-concentration of the formulation was adjusted to 100 μ g/ml. The obtained mRNA-LNP formulations were stored at -80 °C until further in vitro or in vivo use.

Example 4: Example 4: Formulation of FLuc mRNA in lipid nanoparticles (PTX_LNP#4) for in vivo applications by intramuscular, subcutaneous or intradermal administration

[00336] For in vivo experiments, mRNA-LNPs were prepared in a formulation process with β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide as cationic lipid. Alternatively, other cationic lipids like L-Arginyl- β -alanine-N-palmityl-N-oleyl-amide can be used in an identical procedure to prepare similar mRNA-LNPs.

[00337] A lipid solution was prepared by dissolving the lipid components 2 β -(L-arginyl)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide: CHEMS: Cholesterol : mPEG-2000-DMPE at a molar ratio of 29:48:18:5 in ethanol. Subsequently, this lipid solution was mixed with a solution of CleanCap® FLuc mRNA (5moU; Trilink Biotechnologies, San Diego) in acetate buffer (50 mM, pH 4) at a volume ratio (RNA solution: lipid solution) of 2:1 using a microfluidic mixer (NanoAssemblr®; Precision Nanosystems, Vancouver, BC), applying an overall flow rate of 18 ml/min. The applied lipid and mRNA concentrations were adjusted in a way, that the total lipid to mRNA mass ratio of the thus obtained mRNA formulation equals 32. After the mixing process, the formulations were dialyzed against 10 mM TRIS buffered 270 mM Sucrose solution using 3.5 kDa MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher Scientific). The formulation in the floating dialysis cassette was dialyzed for 2 hours at room temperature while gently stirring the dialysis buffer; the dialysis buffer was changed and dialyzed for another 2 hours at room temperature. Once again, the dialysis buffer was changed and dialyzed at 4 °C overnight. During the dialysis procedure, a total dialysis buffer of at least 300 times the volume of the sample was used. Instead of Sucrose, other sugars like Trehalose or Glucose can equally be used within the formulation process.

[00338] Subsequently, the thus obtained formulation was tested for particle size (Zetasizer Ultra instrument (Malvern Instruments Ltd, Malvern, UK), RNA encapsulation (Quant-iT RiboGreen RNA Assay Kit following manufacturer's (Thermo Fisher Scientific) protocol, and endotoxin content. Particle sizes were found to be between 40 to 90 nm (Z-Average) having a Zeta-potential of 0 mV $\pm$ 10 mV. The formulation displayed greater than 90 % mRNA encapsulation. At this point, the final mRNA-concentration of the formulation was adjusted to 100 μ g/ml. The obtained mRNA-LNP formulations were stored at -80 °C until further in vitro or in vivo use.

Example 5: In vivo assessment of Luciferase expression after intramuscular injection of different PTX_LNPs into mice.

[00339] To assess the firefly luciferase (FLuc) expression after intramuscular injection of the various PTX_LNP's, a mouse study was designed as schematically depicted in Fig. 1. The group designation is shown in the following table, namely, group A was a saline group without any FLuc-mRNA serving as a vehicle control. Group B was the mere FLuc-mRNA without any lipids serving as a control, Group C was an overall positively charged FLuc-mRNA-LNP

prepared as described in Example 1. Group D was an overall positively charged FLuc-mRNA-LNP prepared as described in Example 2. Group E was an overall neutral FLuc-mRNA-LNP according to the underlying invention which was prepared as described in Example 3 and which comprises 2 mol% mPEG2000-DMPE. Group F is an overall neutral FLuc-mRNA-LNP according to the underlying invention which was prepared as described in Example 4 and which comprises 5 mol% mPEG2000-DMPE. Group G was a neutral FLuc-mRNA-LNP based on an ionizable cationic lipid of the prior art. For said groups the luciferase expression was assessed 24 hours post injection, whereas for groups H to M, comprising the same samples as groups B to G, the luciferase expression was assessed 72 hours post injection. Each group consisted of three 8-10 weeks old C57BL/6 mice.

[00340] For treatment, the mice received per thigh (left & right hindlimb) 6x10 μ l of each test substance as outlined in the Table 1 below by intramuscular injection using Omnican 50U-100 syringes with 30G needles (0.30 mm x 12 mm). Therefore, prior to injection the thighs were shaved, and mice received 6 x 10 μ l injections per thigh muscle in a distance of approximately 2-3 mm each with the cannula applied 4-5 mm deep into the muscle tissue.

[00341] 24 hours or 72 hours respectively, mice were sacrificed, and the total thigh muscle tissue was snap-frozen in liquid nitrogen. For luciferase assay, the frozen muscle tissue was pulverized in a dry-ice pre-cooled mortar and 60-90mg of the tissue was homogenized in PROMEGA Luciferase Cell Culture Lysis lysis buffer (10 μ l/mg tissue powder) for 5min/50Hz using a bead raptor (QIAGEN TissueLyser LT).

[00342] The homogenates were centrifuged and the expressed luciferase in the supernatants was measured using the PROMEGA Nano-Glo® Dual-Luciferase® Reporter Assay System kit. In brief, undiluted tissue lysate was mixed with an equal volume of luciferin containing assay buffer and luminescence was measured immediately using a TECAN infinite 200 Pro luminometer.

[00343] The results are presented in Fig. 2. In comparison to the overall cationic LNP's (PTX_LNP#2 and PTX_LNP#3) and the plain FLuc-mRNA, the overall charge-neutral LNP's (PTX_LNP#3 and PTX_LNP#4) displayed a significantly higher Luciferase expression after intramuscular injection. Furthermore, also compared to the overall charge-neutral LNP of the prior art (based on an ionizable cationic lipid), the overall charge-neutral LNP's according to the underlying invention (PTX_LNP#3 and PTX_LNP#4) showed a significantly higher Luciferase expression after intramuscular injection. Interestingly, for PTX_LNP#4 comprising

a higher amount of mPEG-DMPE lipid (5% versus 2% in PTX_LNP#3), the Luciferase expression after 72 hours was significantly higher than after 24 hours, indicating a sustained biological activity of the PTX_LNP#4.

Table 1: Group designation (dose/timepoints) of mouse experiment for Luciferase expression after intramuscular injection.

	Group	Dose Group µg mRNA/thigh	Sacrifice hours p.t.
A	Saline control	-	24 h
B	FLuc-mRNA*	6 µg (6 x 10 µl)	24 h
C	PTX_LNP#1	6 µg (6 x 10 µl)	24 h
D	PTX_LNP#2	6 µg (6 x 10 µl)	24 h
E	PTX_LNP#3	6 µg (6 x 10 µl)	24 h
F	PTX_LNP#4	6 µg (6 x 10 µl)	24 h
G	LNP#5	6 µg (6 x 10 µl)	24 h
H	FLuc-mRNA*	6 µg (6 x 10 µl)	72 h
I	PTX_LNP#1	6 µg (6 x 10 µl)	72 h
J	PTX_LNP#2	6 µg (6 x 10 µl)	72 h
K	PTX_LNP#3	6 µg (6 x 10 µl)	72 h
L	PTX_LNP#4	6 µg (6 x 10 µl)	72 h
M	LNP#5	6 µg (6 x 10 µl)	72 h

*"naked" CleanCap® FLuc mRNA (5moU) dissolved in 0.9% saline without any lipids at a conc. of 0.100 mg/ml

[00344] The features of the present invention disclosed in the specification, the claims and/or the drawings may both separately and in any combination thereof be material for realizing the invention in various forms thereof.

Claims

1. A preparation for use in therapy,

wherein therapy comprises local administration of the preparation to a subject, wherein the local administration is selected from the group consisting of intramuscular administration, subcutaneous administration and intradermal administration,

wherein the preparation comprises lipid nanoparticles,

wherein the lipid nanoparticles comprise a lipid composition and a therapeutically active agent, and, at a pH of between 7 and 8, are amphoteric overall neutrally charged lipid nanoparticles,

wherein the lipid composition comprises a first lipid and a second lipid,

wherein the first lipid is selected from the group consisting of CHEMS (Cholesterol hemisuccinate), an alkyl carboxylic acid, a diacyl glycerol hemisuccinate and a diacyl-phosphatidylserine, wherein preferably the alkyl carboxylic acid is saturated or unsaturated branched or straight alkyl carboxylic acid of 12 to 20 hydrocarbons and wherein preferably the acyl-group is a saturated or unsaturated branched or straight chain alkyl-group of 12 to 20 hydrocarbons

wherein the second lipid is bearing more than one cationic charge at a pH of about 7.2 to about 7.5 preferably at a pH of about 7.4 and wherein the second lipid is preferably selected from the group consisting of β -(L-Arginyl)-L-2,3-diamino propionic acid-N,N-dialkyl-amide and L-Arginyl- β -alanine-N,N-dialkyl-amide, wherein the alkyl chains are independently of each other saturated or unsaturated branched or straight chain alkyl-groups of 12 to 20 hydrocarbons and

wherein the therapeutically active agent is a therapeutically active nucleic acid molecule.

2. The preparation for use of claim 1, wherein the lipid composition comprises a third lipid and/or a fourth lipid, wherein the third lipid is a neutral lipid, and the fourth lipid is a PEGylated lipid.
3. The preparation for use of any one of claims 1 to 2, wherein a surface of the lipid nanoparticles, preferably an outer surface of the lipid nanoparticles, provides about the same number of positive (cationic) charges and of negative (anionic) charges at a neutral pH value of between 6.7 and 7.7.
4. The preparation for use of any one of claims 1 to 3, wherein the molar ratio of the first lipid to the second lipid is such that the number of negative (anionic) charges of the lipid composition and the number of positive (cationic) charges of the lipid composition is about identical at a pH of between 6.7 and 7.7.
5. The preparation for use of any one of claims 2 to 4, wherein the third lipid is (a) a zwitterionic phospholipid selected from the group consisting of phosphatidyl ethanolamine, phosphatidyl choline or (b) an uncharged sterol lipid selected from the group comprising a zoosterol and a phytosterol.
6. The preparation for use of claim 5, wherein the zwitterionic phospholipid is selected from the group consisting of DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DLPE (1,2-Lauroyl-sn-glycero-3-phosphoethanolamine), DPhyPE (1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine), DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), and POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine).
7. The preparation for use of any one of claims 2 to 6, wherein the fourth lipid is selected from the group comprising methoxyPEG-DSPE, methoxyPEG-DMPE, methoxyPEG-DMG, methoxyPEG-DPG, methoxyPEG-DSG, methoxyPEG-c-DMA, 2(methoxyPEG)-N,N-dioctadecylacetamide, 2(methoxyPEG)-N,N-ditetradecylacetamide, methoxyPEG-C8-Ceramide, and methoxyPEG-C16-Ceramide.

8. The preparation for use of any one of claims 2 to 7, wherein the lipid composition comprises:

- CHEMS as the first lipid,
- β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid,
- cholesterol as the third lipid,
- methoxyPEG2000-DMPE as the fourth lipid

9. The preparation for use of any one of claims 2 to 8, wherein the molar ratio of the lipid composition is

(a):

- 20 – 80 mol% of the first lipid
- 20 – 80 mol% of the second lipid
- 10 – 50 mol% of the third lipid, and
- 1 – 10 mol% of the fourth lipid,

wherein the overall lipid content of the lipid composition is 100 mol%, or

(b):

- 20 – 60 mol% of the first lipid
- 20 – 60 mol% of the second lipid
- 10 – 40 mol% of the third lipid, and
- 1 – 5 mol% of the fourth lipid,

wherein the overall lipid content of the lipid composition is 100 mol%.

10. The preparation for use of claim 9, wherein

the lipid composition comprises

- 49 mol% of CHEMS as the first lipid,
- 29 mol% of β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid,
- 20 mol% of cholesterol as the third lipid and
- 2 mol% mPEG2000-DMPE as the fourth lipid;

or

the lipid composition comprises:

- 48 mol% of CHEMS as the first lipid
- 29 mol% of β -(L-Arginyl)-L-2,3-diamino propionic acid-N-palmitoyl-N-oleyl-amide as the second lipid
- 18 mol% of cholesterol as the third lipid and
- 5 mol% of methoxyPEG2000-DMPE as the fourth lipid.

11. The preparation for use of any one of claims 1 to 10, wherein the mean particle size of the lipid nanoparticles is from about 15 nm to about 400 nm, preferably from about 25 nm to about 200 nm and more preferably from about 40 nm to about 100 nm, as determined by means of dynamic light scattering (DLS).

12. The preparation for use of any one of claims 1 to 11, wherein a Zeta-potential of the lipid nanoparticles is from about - 10 mV to about + 10 mV, preferably from about - 5 mV to about + 5mV.

13. The preparation for use of any one of claims 1 to 12, wherein the therapeutically active nucleic acid molecule is selected from the group consisting of an mRNA, a Cas (CRISPR associated endonuclease protein)-encoding mRNA, a plasmid-DNA, a ssDNA (single stranded DNA), an Aptamer, a Spiegelmer, an siRNA molecule, an antisense molecule, an miRNA (micro RNA) molecule, an sgRNA (single guide RNA) molecule, an saRNA (self-amplifying RNA) molecule and a combination thereof.

14. The preparation for use of any one of claims 1 to 13, wherein therapy comprises a method for the treatment and/or prevention of a disease in a subject, and wherein the method

comprises local administration of the preparation to the subject, wherein preferably local administration is selected from the group consisting of intramuscular administration, subcutaneous administration and intradermal administration.

Study design:

- Group size:
 - 3 x C57BL/6 male mice
- 8-10 weeks old
- Administration:
 - intramuscular (*i.m.*)
- Dose concentration:
 - 100µg mRNA/ml
- Dose:
 - 6 x 1µg per thigh in both hindlimb




Fig. 1

Luciferase assay




Fig. 2




Fig. 3

(II)




Fig. 4

(III)




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2023/053639

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A61K48/00	A61K9/00
	A61K31/7052	A61K31/7105
	A61K9/51	C12N15/00
		A61K9/127
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2017/008076 A1 (INSMED INC [US]) 12 January 2017 (2017-01-12) *Formulations 6, 8, 11, 12-17*; example 2; table 8 claims paragraph [0301]; example 5 paragraph [0306]; example 6 paragraph [0310]; example 7 -----	1-14
X	WO 2016/118697 A1 (PHASERX INC [US]) 28 July 2016 (2016-07-28) claims examples -----	1-14
X	WO 2018/126084 A1 (PHASERX INC [US]) 5 July 2018 (2018-07-05) claims 28-96 examples 11-13; tables 2-7 -----	1-14
	-/--	
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 18 April 2023		Date of mailing of the international search report 25/04/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Gerber, Myriam

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2023/053639

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2011/119058 A2 (UNIV DE COIMBRA [PT]; CT DE NEUROCIENCIAS E BIOLOG CELULAR [PT] ET AL.) 29 September 2011 (2011-09-29) examples I, II claims -----	1-14
X	HUANG XIAONAN ET AL: "Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 186, 22 June 2019 (2019-06-22), XP085776181, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2019.107711 [retrieved on 2019-06-22] table 1 figure 1 -----	1-14
A	CHENG XINWEI ET AL: "The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 99, 18 February 2016 (2016-02-18), pages 129-137, XP029445785, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2016.01.022 the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2023/053639

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017008076 A1	12-01-2017	AU 2016291228 A1 AU 2020203367 A1 CA 2989884 A1 EP 3319976 A1 ES 2898340 T3 JP 6884714 B2 JP 2018519818 A US 2018200186 A1 WO 2017008076 A1	07-12-2017 11-06-2020 12-01-2017 16-05-2018 07-03-2022 09-06-2021 26-07-2018 19-07-2018 12-01-2017
WO 2016118697 A1	28-07-2016	AU 2016209295 A1 CA 2974503 A1 CN 107530436 A CN 114642735 A EP 3247328 A1 HK 1248548 A1 JP 7189921 B2 JP 2018509387 A JP 2021050212 A US 2018221402 A1 US 2023038687 A1 WO 2016118697 A1	31-08-2017 28-07-2016 02-01-2018 21-06-2022 29-11-2017 19-10-2018 14-12-2022 05-04-2018 01-04-2021 09-08-2018 09-02-2023 28-07-2016
WO 2018126084 A1	05-07-2018	EP 3562510 A1 US 2020078313 A1 WO 2018126084 A1	06-11-2019 12-03-2020 05-07-2018
WO 2011119058 A2	29-09-2011	NONE	